

3-6-00

A

-1-



Express Mail Label No. EL488339843US  
Date of Deposit: March 3, 2000

File No.: 96-41D1  
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prior Application: 08/991,890

Examiner: C. Saoud

Group Art Unit: 1646



Filing Under 37 C.F.R. §1.53(b)

Box Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

1. ☒ This is a request for filing a:  
☐ Continuation  
☒ Divisional

application under 37 C.F.R. §1.53(b), of pending prior application  
Serial No. 08/991,890 filed on December 16, 1997, which claimed  
priority of Serial No. 60/033,003, filed on December 16, 1996.

2. ☒ The copy of the papers of the prior application as filed which are  
attached are as follows:  
☒ 63 pages of specification  
☒ 4 sheets of Dec. and Power of Attorney  
☒ 2 sheets of Figures  
☒ 7 pages of sequence listing
3. ☐ Cancel in this application original claims \_\_\_\_\_ of the prior  
application before calculating the filing fee.

4. ☐ A Preliminary Amendment is enclosed.


**CALCULATION OF APPLICATION FEE**

Claim Type	No. Filed	Less	Extra	Extra Rate	Fee
Total	15	-20	0	\$18.00	\$000.00
Independent	7	-3	4	\$78.00	\$312.00
Basic Fee					\$690.00
Multiple Dependency Fee If Applicable (\$260.00)					\$000.00
<b>Total Filing Fee</b>					<b>\$1,002.00</b>

5. ☒ Please charge the required fee, estimated to be \$1,002.00 to ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.
6. ☐ Please abandon prior application Serial No. \_\_\_\_\_ at a time while the prior application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending and has been granted a filing date, so as to make this application co-pending with said prior application.
7. ☐ Transfer the drawing(s) from the prior application to this application.
8. ☐ New drawings are enclosed: ( ) formal ( ) informal
9. ☐ Priority of this application Serial No. \_\_\_\_\_ filed on \_\_\_\_\_ in \_\_\_\_\_ is claimed under 35 U.S.C §119.
- a. ☐ A certified copy thereof is submitted herewith.
- b. ☐ A certified copy thereof was filed in the prior application.
10. ☐ Enclosed is a petition and fee to extend the term in the pending prior application until \_\_\_\_\_.
11. ☒ Amend the specification by inserting before the first line the sentences:  
This is a  
☐ continuation  
☒ divisional  
application of co-pending application Serial No. 08/991,890, filed December 16, 1997, which is related to Provisional Application 60/033,003, filed on December 16, 1996. Under 35 U.S.C. § 119(e)(1), this application claims benefit of said Provisional Application.
12. ☒ The prior application is assigned of record to ZymoGenetics, Inc. recorded on May 4, 1999 Reel 9953, Frame 607.

13. [X] The Power of Attorney in the prior application is to Gary E. Parker, Deborah A. Sawislak, Debra K. Leith, Roberta A. Picard, Paul G. Lunn and Susan E. Lingenfelter. **Address all future communications to Deborah A. Sawislak, Patent Department, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, Washington 98102.**
14. [ ] Enclosed is an ASCII Computer Disk Sequence Pursuant to 37 CFR 1.821(f). It is believed that the content of the paper sequence listing and the computer readable sequence listing are the same.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



Deborah A. Sawislak  
Registration No. 37,438

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

Re: U.S. Patent Application for  
COMPOSITIONS AND METHODS FOR STIMULATING PANCREATIC  
ISLET CELL REGENERATION

Applicants: Stephen R. Jaspers, Katherine H. Sprugel, Hong Ping Ren,  
Jacqueline M. Humes, Ross C. Hoffman, Darrell C. Conklin

Sir:


Express Mail Label No. EL488339843US

Date of Deposit March 3, 2000

I hereby certify that the following attached paper(s) or fee

1. Return Post card
2. Filing Under 37 C.F.R. §1.53(b) (in duplicate)
3. Patent Application (63 pages)
4. Figures (2 sheets of drawings)
5. Copy of Executed Declaration and Power of Attorney
6. Sequence Listing (7 pages)
7. Letter

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above, addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

  
\_\_\_\_\_  
Amy Toman

Mailing Address:

ZymoGenetics, Inc  
1201 Eastlake Avenue East  
Seattle, WA 98102  
(206) 442-6600

File Number: 96-41D1  
Filing Date: March 3, 2000  
Express Mail Label No. EL488339843US

UNITED STATES PATENT APPLICATION

OF

Stephen R. Jaspers, Katherine H. Sprugel, Hong Ping Ren,  
Jacqueline M. Humes, Ross C. Hoffman, Darrell C. Conklin

FOR

COMPOSITIONS AND METHODS FOR STIMULATING PANCREATIC ISLET CELL  
REGENERATION

## DESCRIPTION

5     Compositions and Methods for Stimulating Pancreatic Islet  
Cell Regeneration

## BACKGROUND OF THE INVENTION

10             $\beta$ -cells are specialized cells that secrete insulin and are found in pancreatic islets. Insulin belongs to a group of protein/polypeptide hormones. Insulin increases the rate of synthesis of glycogen, fatty acids, and proteins and stimulates glycolysis and cell  
15 proliferation. It also promotes the transport of glucose, and some other sugars, and amino acids into muscle and fat cells. Insulin levels are regulated to maintain glycemic homeostasis, and an important mechanism for regulating insulin production, and hence insulin levels, is  $\beta$ -cell  
20 mass.

During the lifetime of an individual metabolic needs can change drastically, requiring dynamic changes in cells and tissues that regulate homeostasis. During pregnancy (Marynissen et al., Diabetes 36:883-891, 1987)  
25  $\beta$ -cell mass increases, as well as in response to obesity (Kloppel et al., Surv. Synth. Pathol. Res. 4:110-125, 1985). These increases in  $\beta$ -cell mass are attributed to an increased requirement for insulin to maintain normal glucose levels (Parsons et al., Endocrinology 130:1459-  
30 1466, 1992). It has also been shown that  $\beta$ -cell mass normally decreases post-partum, primarily by apoptosis (Scaglia et al., Endocrinology 136:5461-5468, 1995).

It is generally believed that increases in  $\beta$ -cell mass occurs in three ways: 1) an increase in cell  
35 size and function; 2) increased proliferation of mature  $\beta$ -cells; and/or 3) increased recruitment and differentiation of  $\beta$ -cell progenitors. In diabetic mice, animals that

received islet transplants and then achieved normal glycemia, showed  $\beta$ -cell hypertrophy, rather than an increase in cell replication (Montana et al., J. Clin. Invest. 91:780-787, 1993). Adult  $\beta$ -cell regeneration has  
 5 been demonstrated in rodents (Hellerstrom et al., in "The Pathology of the Endocrine Pancreas in Diabetes", P.J. Lefebvre and D.G. Pipeleers, eds., pp. 141-170, Springer-Verlag, Heidelberg, 1988). In partially pancreatectomized rats both preexisting  $\beta$ -cells, as well as proliferation  
 10 and differentiation of precursor cells, have been demonstrated to expand (Bonner-Weir, Diabetes Nutr. Res. 5, Supp.1:21-25, 1992).

Several factors have been shown to increase  $\beta$ -cell mass. These factors include glucose (Woerner, Anal. Rev. 71:33-57, 1938), IGF-I (Rabinovitch et al., Diabetes 31:160-164, 1982), reg protein (Terazono et al., J. Biol. Chem. 263:2111, 1988) and possibly a combination of TGF- $\alpha$  and gastrin (Bonner-Weir, Recent Prog. Hormone Res. 49:91-104, 1994). While some factors have been shown to  
 15 increase  $\beta$ -cell mass *in vitro* or *in vivo*, understanding of the process is poorly understood and the possibility that other unidentified factors are involved is likely.  
 20

Recently a new member of the insulin superfamily has been identified, early placenta insulin-like factor or placentin (Chassin et al., Genomics 29:465-470, 1995). Placentin cDNA was isolated from first trimester human placenta and found to have a 139-amino acid open reading frame. Based on homology to the rest of the insulin superfamily it was predicted that placentin, like  
 25 preprorelaxin and preproinsulin, would have a signal sequence, followed by the B chain, C peptide, A chain. The mature molecule would have the signal peptide and C peptide removed, with the B and A chains joined by both inter- and intra-chain disulfide bonds (Chassin et al.,  
 30 1995, *ibid.* and James et al., Nature 267:544-546, 1977). The B-chain, C-peptide, A-chain motif is found in several  
 35

other proteins, including relaxin (U.S. Patent No. 4,835,251), insulin-like growth factors (IGF) I and II (Bang and Hall, in "Insulin-like Growth Factors", P.N. Schofield (ed.), pp. 151-177, Oxford University Press, 5 Oxford, 1992), and Leydig Factor (Bullesbach et al., J. Biol. Chem. 270:16011-16015, 1995). Unlike other members of the insulin superfamily, IGF I and IGF II have D and E domains that are cleaved post-translationally. Cysteines that are involved in disulfide bonds are conserved in all 10 the members of the family and play a role in the tertiary structure of the molecules.

Placentin has been shown to stimulate <sup>3</sup>H-thymidine uptake in human placental 3AsubE cells and stimulate human chorionic gonadotropin production in 15 primary cultures of trophoblasts (Koman et al., J. Biol. Chem. 271:20238-20241, 1996). This activity suggests that placentin may play a role during placental development. However, the present inventors, surprisingly, have found that a molecule encoded by the DNA for placentin, but a 20 different amino acid structure, increases  $\beta$ -cell mass and may be useful in treatment of diabetes, and further that the biologically active molecule differs from the molecule described in the art.

## 25 SUMMARY OF THE INVENTION

The present invention provides proteins produced by a method comprising: culturing a host cells into which has been introduced a DNA expression vector comprising a transcription promoter; a DNA segment comprising a 30 nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 76 to nucleotide 417; and a transcription terminator, wherein said host cell expresses the polypeptide encoded by said DNA segment and recovering said protein.

35 In another embodiment, the host is a mammalian cell. In another embodiment, the host has had a second



DNA expression vector introduced into it, wherein the second expression vector comprises a transcription promoter; a DNA segment encoding an endoprotease; and a transcription terminator, wherein said host cell expresses  
 5 the a DNA segment comprising a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 76 to nucleotide 417 and said DNA segment encoded by the endoprotease.

In another aspect, the present invention provides an isolated and purified protein comprising a  
 10 first polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue 110 (Ser) or 114 (Arg); and a second polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 115 (Ser) to residue 139 (Thr), wherein said first  
 15 polypeptide and said second polypeptide are capable of disulfide associating.

In another aspect, the present invention provides an isolated and purified protein comprising a first polypeptide comprising an amino acid sequence as  
 20 shown in SEQ ID NO: 2 from residue 26 (Ala) to residue 48 (Lys), 49 (Thr) or 50 (Phe); and a second polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 115 (Ser) to residue 139 (Thr), wherein said first polypeptide and said second polypeptide are capable  
 25 of disulfide associating.

In another aspect, the present invention provides a method of stimulating proliferation of pancreatic islet comprising administering to a mammal in need thereof, an amount of an isolated and purified  
 30 polypeptide comprising: a first polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue 110 (Ser) or 114 (Arg); and a second polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from amino acid residue 115 (Ser) to residue  
 35 139 (Thr), and wherein said first polypeptide and said second polypeptide are capable of disulfide associating,

sufficient to produce a clinically significant increase in insulin secretory capacity.

In another aspect, the present invention provides a method of stimulating proliferation of pancreatic islets comprising administering to a mammal in need thereof, an amount of an isolated and purified polypeptide comprising: a first polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue 48 (Lys), 49 (Thr) or 50 (Phe); and a second polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from amino acid residue 115 (Ser) to residue 139 (Thr), and wherein said first polypeptide and said second polypeptide are capable of disulfide associating, sufficient to produce a clinically significant increase in insulin secretory capacity.

In other embodiments, the present invention provide methods wherein the clinically significant increase in insulin secretory capacity results in a decrease in fasting plasma glucose levels.

In other embodiments, the present invention provide methods wherein the isolated and purified protein is administered in combination with an insulin sensitizer.

In another aspect, the present invention provides a method for stimulating *in vitro* proliferation of pancreatic islet cells comprising culturing islets with an amount of an isolated and purified protein comprising: a first polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue 110 (Ser) or 114 (Arg); and a second polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from amino acid residue 115 (Ser) to residue 139 (Thr), and wherein said first polypeptide and said second polypeptide are capable of disulfide associating, sufficient to produce an increase in the number of islet cells as compared to islet cells cultured in the absence of the protein.

In another aspect, the present invention provides a method for stimulating *in vitro* proliferation of pancreatic islet cells comprising culturing islets with an amount of an isolated and purified protein comprising:

5 a first polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue 26 (Ala) to residue 48 (Lys), 49 (Thr) or 50 (Phe); and a second polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 2 from amino acid residue 115 (Ser) to

10 residue 139 (Thr), and wherein said first polypeptide and said second polypeptide are capable of disulfide associating, sufficient to produce an increase in the number of islet cells as compared to islet cells cultured in the absence of the protein.

15 In other embodiments, the present invention provides methods wherein said cells are cultured in 0.1 ng/ml to 100 ng/ml of said protein.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 Figure 1 illustrates that animals treated with BHK cells transfected with zins1 have a 50% increase in islet numbers over animals that have been treated with untransfected BHK cells.

Figure 2 illustrates that animals treated with

25 BHK cells transfected with zins1 have a trend toward increased islet size over animals treated with untransfected BHK cells.

#### DETAILED DESCRIPTION OF THE INVENTION

30 Prior to describing the present invention in detail, it may be helpful to define certain terms used herein:

The term "affinity tag" is used herein to denote a peptide segment that can be attached to a polypeptide to

35 provide for purification of the polypeptide or provide sites for attachment of the polypeptide to a substrate.

In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al., *EMBO J.* 4:1075, 1985; Nilsson et al., *Methods Enzymol.* 198:3, 1991), glutathione S transferase (Smith and Johnson, *Gene* 67:31, 1988), substance P, Flag™ peptide (Hopp et al., *Biotechnology* 6:1204-1210, 1988; available from Eastman Kodak Co., New Haven, CT), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general Ford et al., *Protein Expression and Purification* 2: 95-107, 1991, which is incorporated herein by reference. DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

The term "allelic variant" denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

The terms "amino-terminal" and "carboxyl-terminal" are used herein to denote positions within polypeptides and proteins. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide or protein to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a protein is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete protein.

The term "complements of polynucleotide molecules" denotes polynucleotide molecules having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the  
5 sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

The term "contig" denotes a polynucleotide segment equivalent in nucleotide sequence to an EST. A "contig assembly" denotes a collection of EST contigs that  
10 define a larger polynucleotide segment containing an open reading frame encoding a full-length or partial polypeptide.

The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or  
15 more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).

The term "expression vector" denotes a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments may include promoter and  
20 terminator sequences, and may optionally include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

The term "isolated", when applied to a polynucleotide molecule, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within  
35 genetically engineered protein production systems. Such isolated molecules are those that are separated from their

natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985).

When applied to a protein, the term "isolated" indicates that the protein is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated protein is substantially free of other proteins, particularly other proteins of animal origin. It is preferred to provide the protein in a purified form, i.e., greater than 95% pure, more preferably greater than 99% pure.

The term "operably linked", when referring to DNA segments, denotes that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator

The term "ortholog" (or "species homolog") denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

The term "paralog" denotes a polypeptide or protein obtained from a given species that has homology to a distinct polypeptide or protein from that same species.

The term "polynucleotide" denotes a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules.

A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Small polypeptides are commonly referred to as "peptides".

5 A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is  
10 produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

The term "promoter" denotes a portion of a gene  
15 containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

The term "receptor" denotes a cell-associated  
20 protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell. Membrane-bound receptors are characterized by a multi-domain structure comprising an extracellular ligand-binding domain and an intracellular effector domain that  
25 is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked  
30 to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell  
35 adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. Most nuclear receptors also exhibit a

multi-domain structure, including an amino-terminal, transactivating domain, a DNA binding domain and a ligand binding domain. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or  
 5 multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).

The term "secretory signal sequence" denotes a  
 10 DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger peptide is commonly cleaved to remove the secretory peptide during  
 15 transit through the secretory pathway.

All references cited herein are incorporated by reference in their entirety.

20 One aspect of the present invention is based in part on the discovery that an insulin-homolog DNA previously described as placentin encodes a different polypeptide from that described as the placentin protein.

Another aspect of the present invention provides  
 25 methods for administering the novel protein to stimulate pancreatic islet cells to proliferate *in vivo* and *in vitro*. Islet cell proliferation is a measure of increase in  $\beta$ -cell mass. Thus, the molecules of the present invention provide a means for increasing the size and  
 30 number of  $\beta$ -cells ( $\beta$ -cell mass), and thereby increasing insulin availability.

The DNA sequence for placentin was reported to have a 139 amino acid codon open reading frame (WO 95/34653 and Chassin et al., 1995, *ibid.*), and was  
 35 predicted to encode a secretory signal sequence and a mature polypeptide. The mature polypeptide was shown to



have homology with insulin, relaxin 1 and 2, and Leydig Factor, and thus, was considered a member of the insulin superfamily. Within this family, the cysteine motif is highly conserved in the B and A chains, where the B chain motif can be represented as LCGX{10}C, where X{} is the number of any amino acid residues except cysteine (as shown in SEQ ID NO: 6). The A chain motif is CCX{3}CX{8}C, where X{} is the number of any amino acid residues, except cysteine (as shown in SEQ ID NO: 7).

Insulin is synthesized by  $\beta$ -cells of pancreatic islets as preproinsulin, and processing of the mature protein molecule involves cleavage at the C-terminus of the secretory signal polypeptide, and cleavage at the C-terminus of the B chain and at the N-terminus of the A chain, resulting in removal of the C-peptide. The cleavage sites for removal of the secretory signal peptide and C-peptide are not conserved within the insulin superfamily. Chassin et al. (Genomics 29:465-470, 1995) disclosed that the predicted mature placentin molecule would be cleaved at a serine (amino acid residue 17 of SEQ ID NO: 2) to remove the signal peptide and at leucine (amino acid residue 58 of SEQ ID NO: 2) and leucine (amino acid residue 109 SEQ ID NO: 2) to remove the C-peptide.

However, the present inventors predicted a different mature protein, which has been designated Zins1, comprising a disulfide-bonded B chain and A chain, wherein the B chain comprises the amino acid sequence of SEQ ID NO: 2 from amino acid residue 26 (Ala) to at least amino acid residue 43 (Cys) and wherein the A chain comprises the amino sequence of SEQ ID NO: 2 from amino acid residue 115 (Ser) to residue 139 (Thr), based on sequence alignment and analyses. Furthermore, the present inventors have isolated and purified the polypeptide from medium conditioned by host cells co-expressing a first DNA construct comprising the sequence of SEQ ID NO: 1 from nucleotide 1 to nucleotide 420 with a second DNA construct

encoding for endoprotease PC3. PC3 is one of several endoproteases shown to be restricted to endocrine and neuroendocrine tissues and is involved in prohormone processing. The Zins1 protein has demonstrated biological activity that resulted in increased  $\beta$ -cell mass and lowered blood glucose levels.

Analyses of the polypeptides present in the conditioned medium revealed polypeptides comprising a first polypeptide comprising amino acid residue 26 (Ala) to residue 110 (Ser) or 114 (Arg) as shown in SEQ ID NO: 2, and a second polypeptide comprising amino acid residue 115 (Ser) to residue 139 (Thr) as shown in SEQ ID NO: 2. These data suggest that the first polypeptide comprises a B chain and C-peptide and the second polypeptide comprises an A chain, wherein the first and second polypeptides are capable of disulfide associating.

Processing of the mature protein molecule involves cleavage at the C-terminus of the secretory signal peptide, and, based on predicted structural homology with other mature members of the insulin superfamily, a cleavage at the C-terminus of the B chain and at the N-terminus of the A chain, resulting in removal of the C-peptide. Alignment of the deduced amino acid sequence of the Zins1 polypeptide of the present invention with other known members of the insulin superfamily predicts a signal peptide cleavage site at amino acid residue 25 (Ala) of SEQ ID NO:2. Cleavage at the N-terminus of the A chain is predicted to be after amino acid residue 114 (Arg). The cleavage site at the junction of the C-peptide and A chain is highly conserved, occurring after Arg-X-X-Arg (wherein X is any amino acid residue), Arg-Arg or Lys-Arg; however, the cleavage sites at the junction of the signal sequence and B chain, and at the junction of the B chain and C-peptide, do not maintain a similarly high degree of conservation within the insulin family.

The C-peptide portion of insulin superfamily members is highly divergent. Also, the gene encoding Zins1 includes a silent intron of about 2 kb<sup>~</sup> that interrupts the coding sequence in the C-peptide domain, adding another potential variable to the C-peptide portion of Zins1. Zins1 has a 139 amino acid open reading frame, compared to a 110 amino acid open reading frame for human insulin and about 100-200 amino acid open reading frames for other insulin superfamily members. Except for the IGFs (which contain D and E domains), the open reading frame length variations among the members of the insulin superfamily are predominantly associated with C-peptide variations in length.

The enzymology of proinsulin conversion suggests that prohormone convertase 3 (PC3) cleaves primarily at the B chain-C-peptide junction, and that PC2 cleaves preferentially at the C-peptide-A-chain junction and favors proinsulin already processed by PC3 over intact prohormone. In human and rat proinsulin, dibasic residues link the B chain and C-peptide and the C-peptide and A chain. In addition, a basic residue 4 residues N-terminal to the cleavage site (a "P4 basic residue") may be present at one or both junctions, and may influence the ability of PC3, PC2 or furin to cleave at the junction sites. In a study reported by F. Vollenweider et al. (Diabetes 44:1075-80, 1995), cotransfection of COS cells with PC3 and either human proinsulin, rat proinsulin II or mutant human proinsulin Arg<sup>62</sup> showed that PC3 cleaved both proinsulin junctions, regardless of the presence or absence of a P4 basic residue.

Zins1 does not have basic or dibasic residues from position 49 (Thr) to 62 (Gly), as shown in SEQ ID NO: 2. There is an Arg residue at position 63, and a Lys residue at positions 65, 74, 94, 95, 105 and 106. An Arg-Lys-Lys-Arg motif is also present at residues 111-114, just before the A chain start sequence described by the

present invention. Based on sequence alignments, knowledge of prohormone conversion enzymes, and the data presented herein, a B chain-C-peptide junction cannot be definitively determined. Chassin et al. (ibid.) describe a putative cleavage site at the junction of the B chain and C-peptide of placentin (INSL4) between residue 58 (Leu) and residue 59 (Leu) of SEQ ID NO:2. Koman et al. (ibid.) describe a putative cleavage site at the junction of the B chain and C-peptide of placentin between residue 62 (Gly) and residue 63 (Arg) of SEQ ID NO:2. However, neither group provides rationale or data to support cleavage at these sites.

Upon expression of the Zins1 molecule in mammalian cells, the present inventors have discovered that the C-peptide is glycosylated. Carbohydrate analysis revealed that 1 O-glycosylation site is present at either residue 49 (Thr), 50 (Thr), 51 (Thr) or 61 (Ser) of SEQ ID NO: 2. Based on homology with other members of the insulin superfamily, where O-glycosylation has not been identified in any B-chain, the B chain/C-peptide cleavage is predicted to occur after residue 48 (Lys) or residue 49 (Thr) or residue 50 (Phe) of SEQ ID NO: 2, with the O-glycosylation occurring at one of residues 51, 52, 53 or 61. Two more O-glycosylation sites are predicted at residues 69 (Ser), 70 (Thr), and/or 71 (Ser) of SEQ ID NO: 2. Another glycosylation site is predicted at either residue 81 (Thr), 82 (Thr), 83 (Ser) or 90 (Ser) of SEQ ID NO: 2.

While not wanting to be bound by theory, the B chain/C-peptide form of the Zins1 molecule may have an important role in the biological function of the molecule. The B chain/C-peptide may form a domain that is involved in directing the molecule to its target; processing of the molecule to its biologically active form; regulation of receptor multimerization and involvement in formation of tertiary structure, such as folding. In addition, the C-

peptide, particularly in light of the putative glycosylation sites, may function as an independent molecule.

Therefore, the present invention provides  
5 isolated Zins1 proteins that are substantially homologous to the polypeptides of SEQ ID NO: 2. In one embodiment, the isolated and purified Zins1 proteins comprise a first polypeptide (B chain) comprising the amino acid sequence of SEQ ID NO: 2 from amino acid residue 26 (Ala) to at  
10 least amino acid residue 43 (Cys) and a second polypeptide (A chain) comprising the amino sequence of SEQ ID NO: 2 from amino acid residue 115 (Ser) to residue 139 (Thr), wherein said first and second polypeptides are capable of disulfide associating; and their allelic variants and  
15 orthologs.

In another embodiment, the present invention provides isolated and purified Zins1 proteins that comprise a first polypeptide comprising the amino acid sequence of SEQ ID NO: 2 from amino acid residue 26 (Ala)  
20 to an amino acid residue selected from the group consisting of 48 (Lys), 49 (Thr) and 50 (Phe); and a second polypeptide comprising the amino sequence of SEQ ID NO: 2 from amino acid residue 115 (Ser) to residue 139 (Thr), wherein said first and second polypeptides are  
25 capable of disulfide associating; and their allelic variants and orthologs.

In another embodiment, the present invention provides isolated and purified Zins1 protein that comprise a first polypeptide comprising the amino acid sequence of  
30 SEQ ID NO: 2 from amino acid residue 26 (Ala) to amino acid residue 110 (Ser) or 114 (Arg) and a second polypeptide comprising the amino sequence of SEQ ID NO: 2 from amino acid residue 115 (Ser) to residue 139 (Thr), wherein said first and second polypeptides are capable of  
35 disulfide associating; and their allelic variants and orthologs. Cleavage at the C-peptide/A chain junction

occurs at residue 114 (Arg), but carboxypeptidases are well known to remove dibasic residues resulting in the final C-peptide C-terminus being between residue 114 (Arg) and residue 110 (Ser).

5           The term "substantially homologous" is used herein to denote polypeptides having 50%, preferably at least 80%, more preferably 90% identical and most preferably 95% or more identity to the polypeptides as shown in SEQ ID NO: 2

10           Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-616, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992. Briefly, two amino acid sequences are aligned to optimize  
15 the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and Henikoff (ibid.) as shown in Table 1 (amino acids are indicated by the standard one-letter codes).

Table 1

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
A	4																			
R	-1	5																		
N	-2	0	6																	
D	-2	-2	1	6																
C	0	-3	-3	-3	9															
Q	-1	1	0	0	-3	5														
E	-1	0	0	2	-4	2	5													
G	0	-2	0	-1	-3	-2	-2	6												
H	-2	0	1	-1	-3	0	0	-2	8											
I	-1	-3	-3	-3	-1	-3	-3	-4	-3	4										
L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4									
K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5								
M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5							
F	-2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7					
S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4				
T	0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-1	-2	-1	1	5			
W	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11		
Y	-2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1	4

The percent identity is then calculated as:

$$\frac{\text{Total number of identical matches}}{\text{[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences]}} \times 100 =$$

5                    [length of the longer sequence plus the  
number of gaps introduced into the longer  
sequence in order to align the two sequences]

Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above.

10                    Substantially homologous proteins and polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 2) and other  
15                    substitutions that do not significantly affect the folding or activity of the protein or polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide  
20                    of up to about 20-25 residues, or a small extension that facilitates purification, (an affinity tag), such as a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67:31, 1988), maltose binding protein (Kellerman and Ferenci, Methods Enzymol. 90:459-463, 1982; Guan et al., Gene 67:21-30, 1987), or other antigenic epitope or binding domain. See, in general Ford et al., Protein Expression and Purification 2: 95-107, 1991, which is  
25                    incorporated herein by reference. DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ; New England Biolabs, Beverly, MA).

30



Table 2Conservative amino acid substitutions

5	Basic:	arginine
		lysine
		histidine
	Acidic:	glutamic acid
		aspartic acid
10	Polar:	glutamine
		asparagine
	Hydrophobic:	leucine
		isoleucine
		valine
15	Aromatic:	phenylalanine
		tryptophan
		tyrosine
	Small:	glycine
		alanine
20		serine
		threonine
		methionine

The proteins of the present invention can also comprise non-naturally occurring amino acid residues. Non-naturally occurring amino acids include, without limitation, *trans*-3-methylproline, 2,4-methanoproline, *cis*-4-hydroxyproline, *trans*-4-hydroxyproline, *N*-methylglycine, *allo*-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, *tert*-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods

for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is carried out in a cell free system comprising an *E. coli* S30 extract and commercially available enzymes and other reagents. Proteins are purified by chromatography. See, for example, Robertson et al., J. Am. Chem. Soc. 113:2722, 1991; Ellman et al., Methods Enzymol. 202:301, 1991; Chung et al., Science 259:806-809, 1993; and Chung et al., Proc. Natl. Acad. Sci. USA 90:10145-10149, 1993). In a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., J. Biol. Chem. 271:19991-19998, 1996). Within a third method, *E. coli* cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring amino acid is incorporated into the protein in place of its natural counterpart. See, Koide et al., Biochem. 33:7470-7476, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by *in vitro* chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, Protein Sci. 2:395-403, 1993).

Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244, 1081-1085, 1989; Bass et al., Proc. Natl. Acad. Sci. USA 88:4498-4502, 1991). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g.,

proliferation of islet or  $\beta$ -cells) to identify amino acid residues that are critical to the activity of the molecule.

Other methods that can be used include phage display (e.g., Lowman et al., Biochem. 30:10832-10837, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis (Derbyshire et al., Gene 46:145, 1986; Ner et al., DNA 7:127, 1988).

Mutagenesis methods as disclosed above can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides in host cells. Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

Using the methods discussed above, one of ordinary skill in the art can prepare a variety of mature, biologically active polypeptides that are derived from polynucleotides that are substantially homologous to nucleotides 76 to 417 of SEQ ID NO: 1 or allelic variants thereof and retain the properties of the wild-type protein to stimulate islet proliferation, differentiation and/or metabolic processes.

Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly culture cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor

Laboratory Press, Cold Spring Harbor, NY, 1989, and Ausubel et al., *ibid.*, which are incorporated herein by reference.

In general, a DNA sequence encoding a Zins1 polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

To direct a Zins1 polypeptide into the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of the Zins1 polypeptide, or may be derived from another secreted protein (e.g., t-PA) or synthesized *de novo*. The secretory signal sequence is joined to the Zins1 DNA sequence in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

If Zins1 polypeptide is expressed in a non-endocrine or non-neuroendocrine cell, the expression host cell generally will not express the prohormone convertases PC2 and PC3, which are believed to be involved in the

regulated secretory pathway. Another member of this endoprotease family, furin, is present in most cells and is believed to be involved in the constitutive secretory pathway. F. Vollenweider et al. have described the role of these prohormone conversion endoproteases in general, and specifically describe studies involving co-transfection of COS cells with proinsulin and one of the endoproteases (Diabetes 44:1075-80, 1995). Their results showed that PC3 and furin were able to cleave proinsulin at both its junctions; PC2 did not exhibit prohormone cleavage to any significant extent. Without co-transfection of an endoprotease, the prohormone was not converted to any great extent by COS cells. However, the co-transfection system described is still not an exact model of the natural  $\beta$  cell environment, since  $\beta$  cells make both PC2 and PC3. Also, a non-endocrine cell does not represent a native environment for PC2 and PC3 expression. In addition, co-transfection may result in general or local overexpression of PC2 and/or PC3, relative to the native  $\beta$  cell environment. In a preferred embodiment, the host cells will be co-transfected with a second DNA expression construct comprising the following operably linked elements: a transcription promoter; a DNA segment encoding an endoprotease; and a transcription terminator, wherein the host cell expresses the DNA segment encoding the endoprotease.

Cultured mammalian cells are preferred hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987), and liposome-mediated

transfection (Hawley-Nelson et al., Focus 15:73, 1993; Ciccarone et al., Focus 15:80, 1993), which are incorporated herein by reference. The production of recombinant polypeptides in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134, which are incorporated herein by reference. Preferred cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978, which are incorporated herein by reference) and the adenovirus major late promoter.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of

the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used.

Other higher eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells. Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al., U.S. Patent No. 4,775,624; and WIPO publication WO 94/06463, which are incorporated herein by reference. The use of *Agrobacterium rhizogenes* as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987.

Fungal cells, including yeast cells, and particularly cells of the genus *Saccharomyces*, can also be used within the present invention, such as for producing Zins1 fragments or polypeptide fusions. Methods for transforming yeast cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075, which are incorporated herein by reference. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g. leucine). A preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Suitable

promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092, which  
 5 are incorporated herein by reference) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454, which are incorporated herein by reference. Transformation systems for other yeasts, including *Hansenula polymorpha*,  
 10 *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., J. Gen. Microbiol. 132:3459-3465, 1986 and Cregg, U.S. Patent No. 4,882,279.  
 15 *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349, which is incorporated herein by reference. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228, which is  
 20 incorporated herein by reference. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533, which is incorporated herein by reference.

Transformed or transfected host cells are  
 25 cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon  
 30 source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in  
 35 an essential nutrient which is complemented by the



selectable marker carried on the expression vector or co-transfected into the host cell.

Zins1 polypeptides can also be used to prepare antibodies that specifically bind to Zins1 epitopes, peptides or polypeptides. Methods for preparing polyclonal and monoclonal antibodies are well known in the art (see, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY 1989; and Hurrell, J. G. R., Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Inc., Boca Raton, FL, 1982, which are incorporated herein by reference). As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from a variety of warm-blooded animals, such as humans, horses, cows, goats, sheep, dogs, chickens, rabbits, mice and rats.

The immunogenicity of a Zins1 polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of Zins1 polypeptides or a portion thereof with an immunoglobulin polypeptide or with a maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "haptent-like", such a portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

As used herein, the term "antibodies" includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as  $F(ab')_2$  and Fab proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-

binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting only non-human CDRs onto human framework and constant regions, or incorporating the entire non-human variable domains  
 5 (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper  
 10 binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced. Alternative techniques for generating or selecting antibodies useful herein include in vitro  
 15 exposure of lymphocytes to Zins1 polypeptides or peptides, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled Zins1 polypeptide or peptide).

Antibodies are defined to be specifically  
 20 binding if they bind to a Zins1 polypeptide with a binding affinity ( $K_a$ ) of  $10^6 \text{ M}^{-1}$  or greater, preferably  $10^7 \text{ M}^{-1}$  or greater, and most preferably  $10^9 \text{ M}^{-1}$  or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art (for example, by  
 25 Scatchard analysis).

A variety of assays known to those skilled in the art can be utilized to detect antibodies which specifically bind to Zins1 polypeptides or peptides. Exemplary assays are described in detail in Antibodies: A  
 30 Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot  
 35 assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for

binding to wild-type versus mutant Zins1 polypeptides or peptides.

Antibodies to Zins1 polypeptides may be used for tagging cells that express Zins1 polypeptides; for  
5 isolating Zins1 polypeptides by affinity purification; for diagnostic assays for determining circulating levels of Zins1 polypeptides; for detecting or quantitating soluble Zins1 polypeptides as marker of underlying pathology or disease; in analytical methods employing FACS; for  
10 screening expression libraries; for generating anti-idiotypic antibodies; for localization by immunocytochemistry; and as neutralizing antibodies. Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent  
15 markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anticomplement pairs as intermediates. Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and  
20 the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications.

Zins1 polypeptide prepared according to the present invention is purified using methods generally known in the art, such as affinity purification and  
25 separations based on size, charge, solubility and other properties of the protein. When the protein is produced in cultured mammalian cells, it is preferred to culture the cells in a serum-free culture medium in order to limit the amount of contaminating protein. The medium is  
30 harvested and fractionated. Preferred methods of fractionation include affinity chromatography, Q-Fast Flow Sepharose, MonoQ resin, FPLC, phenyl Sepharose, hydroxyapatite, Mono S and/or S-Sepharose.

Molecules of the present invention can be used  
35 to identify and isolate receptors for Zins1. For example, proteins and peptides of the present invention can be

immobilized on a column and membrane preparations run over the column (Immobilized Affinity Ligand Techniques, Hermanson et al., eds., Academic Press, San Diego, CA, 1992, pp.195-202). Proteins and peptides can also be radiolabeled (Methods in Enzymol., vol. 182, "Guide to Protein Purification", M. Deutscher, ed., Acad. Press, San Diego, 1990, 721-737) or photoaffinity labeled (Brunner et al., Ann. Rev. Biochem. 62:483-514, 1993 and Fedan et al., Biochem. Pharmacol. 33:1167-1180, 1984) and specific cell-surface proteins can be identified.

Antibodies to Zins1 proteins and peptides may be used for affinity purification, for diagnostic assays, for determining circulating levels of Zins1 polypeptides and as antagonists to block Zins1 binding and signal transduction *in vivo* and *in vitro*.

Proteins of the present invention are useful for stimulating proliferation or differentiation of pancreatic islets and their component cells which include  $\alpha$ -cell,  $\beta$ -cells and  $\delta$ -cells. Proliferation and differentiation can be measured *in vitro* using cultured cells or *in vivo* by administering molecules of the claimed invention to the appropriate animal model. For instance, Zins1 transfected or Zins1-endoprotease co-transfected expression host cells may be embedded in an alginate environment and injected (implanted) into recipient animals. Alginate-poly-L-lysine microencapsulation, permselective membrane encapsulation and diffusion chambers have been described as a means to entrap transfected mammalian cells or primary mammalian cells. These types of non-immunogenic "encapsulations" or microenvironments permit the transfer of nutrients into the microenvironment, and also permit the diffusion of proteins and other macromolecules secreted or released by the captured cells across the environmental barrier to the recipient animal. Most importantly, the capsules or microenvironments mask and shield the foreign, embedded cells from the recipient

animal's immune response. Such microenvironments can extend the life of the injected cells from a few hours or days (naked cells) to several weeks (embedded cells). The alginate threads described herein provide a simple and quick means for generating embedded cells. The materials needed to generate the alginate threads are readily available and relatively inexpensive. Once made, the alginate threads are relatively strong and durable, both *in vitro* and, based on data obtained using the threads, *in vivo*. The alginate threads are easily manipulatable and the methodology is scalable for preparation of numerous threads.

Molecules of the present invention are useful as a reagent for *in vitro* culturing of islets, and hence their component cells which include  $\alpha$ -cell,  $\beta$ -cells and  $\delta$ -cells, *in vitro*, which have been difficult to grow. Cultured islets provide islet cells for transplantation, an alternative to whole pancreas transplantation. Assays measuring cell proliferation or differentiation are well known in the art. For example, assays measuring proliferation include such assays as chemosensitivity to neutral red dye (Cavanaugh et al., Investigational New Drugs 8:347-354, 1990, incorporated herein by reference), incorporation of radiolabelled nucleotides (Cook et al., Analytical Biochem. 179:1-7, 1989, incorporated herein by reference), incorporation of 5-bromo-2'-deoxyuridine (BrdU) in the DNA of proliferating cells (Porstmann et al., J. Immunol. Methods 82:169-179, 1985, incorporated herein by reference), and use of tetrazolium salts (Mosmann, J. Immunol. Methods 65:55-63, 1983; Alley et al., Cancer Res. 48:589-601, 1988; Marshall et al., Growth Reg. 5:69-84, 1995; and Scudiero et al., Cancer Res. 48:4827-4833, 1988; all incorporated herein by reference). Assays measuring differentiation include, for example, measuring cell-surface markers associated with stage-specific expression of a tissue, enzymatic activity,

functional activity or morphological changes (Watt, FASEB, 5:281-284, 1991; Francis, Differentiation 57:63-75, 1994; Raes, Adv. Anim. Cell Biol. Technol. Bioprocesses, 161-171, 1989; all incorporated herein by reference).

5           Zins1 may also have other insulin-like activities, affecting glucose and lipid metabolism. Assays to measure other cellular responses, that include chemotaxis, adhesion, changes in ion channel influx, regulation of second messenger levels and neurotransmitter  
10 release are well known in the art. See, for example, in "Basic & Clinical Endocrinology Ser., Vol. Vol. 3," Cytochemical Bioassays: Techniques & Applications, Chayen; Chayen, Bitensky, eds., Dekker, New York, 1983.

Treatment of diabetes using Zins1 will be  
15 particularly useful for gestational and Type II (NIDDM) diabetes. In gestational and Type II diabetes, the disease is characterized by defects in both insulin action (also referred to as insulin resistance) and insulin secretion. In some patients, the use of Zins1 alone may  
20 be sufficient to eliminate the requirement for exogenous insulin or insulin secretagogues (oral hypoglycemic agents). Zins1 may be used in conjunction with insulin, with insulin sensitizing agents, and oral hypoglycemic agents or with combinations thereof. Troglitazone is an  
25 example of an insulin sensitizing agent. In an exemplary Zins1-insulin sensitizer combined treatment, the recipient's insulin resistance is reduced, thereby decreasing the insulin secretion demand, and insulin secretion capacity is enhanced by increases in  $\beta$ -cell  
30 mass. Such a treatment provides a  $\beta$ -cell reserve and results in effective treatment for gestational and Type II diabetes. Zins1 may provide treatment for Type I diabetes, if treatment includes suppression of autoantigenic destruction of  $\beta$ -cells once they are  
35 stimulated to proliferate and increase in function.

For pharmaceutical use, the proteins of the present invention are formulated for parenteral, particularly intravenous, or subcutaneous, delivery according to conventional methods. Insulin formulations are known in the art and can provide guidance for molecules of the present invention. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. In general, pharmaceutical formulations will include a mature Zins1 protein in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton PA, 1990, which is incorporated herein by reference. Therapeutic doses will generally be in the range of 0.1 to 100 µg/kg of patient weight per day, preferably 0.5-20 µg/kg per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art. The proteins may be administered for acute treatment, over one week or less, often over a period of one to three days. In the treatment of diabetes, the molecules of the present invention would be used in chronic treatment, over several months or years. In gestational diabetes, chronic administration would generally be for weeks. In general, a therapeutically effective amount of Zins1 is an amount sufficient to produce a clinically significant change in insulin secretory capacity. In a patient, insulin secretory capacity is determined by fasting plasma glucose levels or glucose tolerance. Generally, fasting plasma

glucose levels equal to, or more than, 126 mg/dl indicate diabetes. Impaired glucose tolerance is diagnosed when 2-hour plasma glucose levels from a oral glucose tolerance tests are greater than, or equal to, 140 mg/dl, but less than 200 mg/dl. Above 200 mg/dl, diabetes is diagnosed. Generally, treatment would begin when fasting plasma glucose levels are above 126 mg/dl. Normal plasma glucose levels are 115 mg/dl, according to standards set by the American Diabetes Association.

The invention is further illustrated by the following non-limiting examples.

#### Examples

##### Example 1. Expression of a Biologically Active Zins1

The Zins1 cDNA was isolated from a human placental library using PCR and designated Zins1. The Zins1 cDNA sequence was prepared in a mammalian expression vector with either a N-terminal or C-terminal poly-His tag. The mammalian expression vector was modified from a vector designated pHZ-200. pHZ-200 was derived from a mammalian expression vector designated pHZ-1 with the only modification being that the dihydrofolate reductase sequence was substituted for the neomycin resistance gene. Plasmid pHZ-1 is an expression vector used to express protein in mammalian cells or in a frog oocyte translation system from mRNAs that have been transcribed *in vitro*. The pHZ-1 expression unit comprises the mouse metallothionein-1 promoter, the bacteriophage T7 promoter flanked by multiple cloning banks containing unique restriction sites for insertion of coding sequences, the human growth hormone terminator and the bacteriophage T7 terminator. In addition, pHZ-1 contains an *E. coli* origin of replication; a bacterial beta lactamase gene; a mammalian selectable marker expression unit comprising the



SV40 promoter and origin, a neomycin resistance gene and the SV40 transcription terminator.

The vector used for the N-terminal His tagged Zins1, was designated pOZ2, and contained at the 5' end of the cloning site, a tPA leader followed by six histidine residues and a four amino acid spacer (GGSG), as shown in SEQ ID NO: 4 from amino acid residue 36 to residue 45. The final Ser, Gly residues of the spacer constitute a BspE1 restriction site, allowing for insertion of the desired cDNA with no extra residues. The downstream 3' cloning site was Xho1. The zins1 sequence was inserted into the BspE1/Xho1 site directionally with the predicted mature end of the protein at the 5' end amino acid residue 26 (Ala) of SEQ ID NO: 2. The Xho site occurs directly after an in-frame stop codon. This construct was designated Zins1pOZ2.

The C-terminal His tagged Zins1 construct was made in pOZ1. This vector is pHZ-200 based with a Kpn1 site at the 5' end of the cloning site. At the 3' end the vector contains an in-frame spacer (GS GG) followed by six histidine residues. The first two residues of the spacer (GS) constitute a BamHI site which allows for insertion of the cDNA of interest with no extra residues. The zins1 sequence, containing the native leader sequence, was inserted directionally using the Kpn1/BamHI site. A stop codon occurs after the final His residue. This construct was designated Zins1pOZ1.

The zins1 cDNAs were each co-transfected into BHK 570 cells (ATCC accession no. 10314) along with cDNA encoding one of two different conversion endoproteases known to be involved in prohormone processing. These two enzymes, PC2 and PC3, have been shown to be restricted to endocrine and neuroendocrine tissues and cells, with PC3 resulting in more extensive processing of insulin from its prohormone to active form.

A total of four transfections were performed:

- 1) zins1pOZ1/PC2 (called zins1C/PC2)
- 2) zins1pOZ1/PC3 (called zins1C/PC3)
- 3) zins1pOZ2/PC2 (called zins1N/PC2) and
- 4) zins1pOZ2/PC3 (called zins1N/PC3).

5           10 µg of each DNA prep (20 µg total) was transfected into subconfluent BHK570 cells using lipofectamine reagent (GIBCO-BRL, Gaithersburg, MD), according to the manufacturer's specifications. The following day the transfected cells were trypsinized, and  
10 split at several dilutions up to 1:160. The medium was replaced with growth media (Table 3) containing both 1 µM methotrexate (MTX) and 1X G418 (neomycin). The pOZ plasmids contain the DHFR gene conferring resistance to MTX and the plasmid containing the PC enzyme contains the  
15 neomycin resistance gene. After several weeks, transfectant pools that had been cultured in 1 µM MTX + G418, and approximately 12 individual clones from each transfection were selected for further analyses.

Serum-free conditioned media (Table 4) from each  
20 of the pools and clones were analyzed for reactivity with an antibody made to a zins1/MBP fusion protein. The recombinant zins1 protein was affinity purified from the spent culture media using Ni-NTA agarose (Qiagen, Chatsworth, CA). Purification was done using a batch  
25 process, where 200 µl of Ni resin was added to 5 ml of conditioned media and incubated overnight on a rocking platform at 4°C. The resin was washed 2 times and the proteins eluted directly into 2X tricine gel sample buffer. The samples were electrophoresed on 16% Novex  
30 tricine gels and blotted onto nitrocellulose. The blots were incubated overnight in a 1:2000 (0.5 µg/ml) dilution of the fusion protein antibody.

The blots revealed a broad band of immunoreactivity between 10-18 kDa under reducing  
35 conditions, with distinct bands at 3 and 6 kDa in some lanes. Several clones were picked for further analysis;

zins1N/PC3#4, zins1N/PC3#3, zins1N/PC3#9, zins1N/PC2#1, zins1C/PC2#2, zins1C/PC3#9, and zins1C/PC3#1.

N-terminal amino acid sequencing was performed on several clones. Two bands were sequenced from zins1N/PC2 #1. The lower band (~3 kDa) was found to have the sequence SGRHRFDPFXXEVIXDDGTSVKL (amino acid residues 115 to 123 of SEQ ID NO: 2, wherein X is Cys), representing the A chain of the molecule. A band slightly above this (~6 kDa) was sequenced and found to be SQEIHAEFQRRHHHHHGGSGAELRGXG (amino acid residues 23 to 52 of SEQ ID NO: 4, wherein X is Cys). The first 13 residues are part of the tPA leader that was not removed in processing.

Several bands were also sequenced from zins1C/PC3#9 (this molecule contained the native leader and a C-terminal His tag). Bands of 14.5, 9.0, 8.0 and 3.5 kDa were sequenced. The first three bands all started with AELRGCG (amino acid residues 26 to 32 of SEQ ID NO: 2), which appeared to be the N-terminus of the mature zins1 protein (B-chain). The 3.5 kDa band started with SGRHRFD (amino acid residues 115 to 121 of SEQ ID NO: 2), representing the N-terminus of the A-chain.

It was believed that a tag on the N-terminus of the B-chain was less likely to interfere with bioactivity than one on the C-terminus of the A-chain. Two clones with relatively high expression of processed protein were chosen for use in the alginate threads assay (see Example 2). These two cell lines, zins1N/PC3#3 and zins1N/PC2#1, differ only by the enzyme co-transfected for prohormone processing. The A-chain produced by these two lines was identical. The B-chain of zins1N/PC2#1 was sequence analyzed and contained some of the tPA leader. Zins1N/PC3#3 demonstrated biological activity in the alginate threads assay (as described in Example 2), and zins1N/PC2#1 did not, suggesting that zins1N/PC3#3 was properly processed in this 'in vivo' assay.

Table 3Growth Medium

500 ml Delbecco's Modified Eagle's Medium (DMEM) (Gibco BRL)

- 5 5% fetal calf serum (Hyclone, Logan, UT)  
 (1mM) sodium pyruvate (Irvine, Santa Ana, CA)  
 (.29 mg/ml) L-glutamine (Hazelton, Lenexa, KS)  
 1x PSN (5 mg/ml penicillin, 5 mg/ml streptomycin,  
 10 mg/ml neomycin) (Gibco BRL, Gaithersburg, MD)

10

Table 4Serum-free Medium

500 ml Dulbecco's Modified Eagle's Medium (DMEM; Gibco BRL)

15

- (1mM) sodium pyruvate (Irvine, Santa Ana, CA)  
 (.29 mg/ml) L-glutamine (Hazelton, Lenexa, KS)  
 (1 mg/ml) vitamin K (Merck, Whitehouse Station, NJ)  
 (10 mg/ml) transferrin (JRH, Lenexa, KS)  
 20 (5 mg/ml) fetuin (Aldrich, Milwaukee, WI)  
 (2 ug/ml) selenium (Aldrich, Milwaukee, WI)

Example 2. In Vivo Testing of Zins1 (Zins1)

25

A. Xenogeneic Cell Transplantation of Zins1 Genei. Preparation of zins1 Alginate Threads

- Briefly, 3% alginate was prepared in USP for  
 30 injection sterile H<sub>2</sub>O (several hours on a rotary shaker at  
 R.T., to get the alginate into solution), and sterile  
 filtered using an 0.8  $\mu$ M filter flask (again, several  
 hours to achieve filtration). Just prior to preparation  
 of alginate threads, the alginate solution was again  
 35 filtered through a 0.45  $\mu$ M syringe tip filter.

A suspension (containing about  $10^6$  to about  $10^8$   
 cells/ml) was mixed at 1:1 vol/vol with the 3% alginate  
 solution. One ml of this alginate/cell suspension was  
 extruded from a 1cc syringe through a 30g needle into a

100 mM  $\text{CaCl}_2$  solution (sterile filtered through a  $0.22 \mu\text{M}$  filter), forming a "thread". The extruded thread was incubated for about 15 min in the 100 mM  $\text{CaCl}_2$  solution; then transferred into a solution of 50 mM  $\text{CaCl}_2$ ; and then  
 5 into a solution of 25 mM  $\text{CaCl}_2$ . The thread was then rinsed with deionized water before incubation in Lactated Ringer's Solution until the time of injection. Finally, the thread in Lactated Ringer's Solution was drawn into a 3cc syringe barrel (without needle attached). A large  
 10 bore needle (16g) was then attached to the syringe, and the thread was intraperitoneally injected into a recipient mouse in ~ 1.5 ml total volume of the Lactated Ringer's Solution.

In one study, each member of a group (containing  
 15 six female, one year old BALB/c mice) was injected with a thread containing either  $1 \times 10^6$  wild type (untransfected) BHK cells;  $2 \times 10^6$  zins1N/PC3#3 co-transfected cells; or  $4 \times 10^6$  zins1N/PC2#1 co-transfected cells. Blood was drawn at days 12 and 15 (non-fasted), and at day 19 (fasted),  
 20 and serum glucose levels (days 12, 15 and 19) and serum insulin levels (days 12 and 15) were determined, as well as cell counts, complete blood chemistries and complete blood counts (CBCs). The animals that received the zins1N/PC3#3 threads showed lower serum glucose levels at  
 25 days 12 and 19 than the wt BHK and zins1N/PC2#1 threads-injected animals. At day 12, the zins1N/PC3#3 threads-injected animals showed elevated serum insulin levels, as compared to the other two groups. Among all of the groups of animals, CBCs were comparable.

30 In a second study, 7 and 6 female BALB/c mice (female, 9 weeks old) were intraperitoneally injected at day 0 with threads containing about  $3 \times 10^7$  untransfected BHK cells or threads containing about  $5 \times 10^6$  zins1N/PC3#3 co-transfected cells, respectively. Another control group  
 35 of 3 animals received no treatment.

All of the animals were fasted prior to being bled on days -3, 8, 12 and 27. For fasting, food was removed at the end of the previous day's light cycle. The animals experienced a dark cycle without food, and then the animals were bled after the beginning of the next light cycle. Thereafter, food was restored. At days 8 and 12, the animals that were injected with zins1N/PC3#3 threads exhibited a significant decrease in serum glucose (35 and 48 mg/dl, respectively), as compared to animals that were injected with wild type BHK cells (65 and 90 mg/dl, respectively). Serum glucose was determined using serum obtained from whole blood collected in non-heparinized tubes. The blood was centrifuged immediately and the serum was analyzed for glucose concentration. Serum triglyceride levels were also significantly higher at days 8 and 12 in the animals that were injected with zins1N/PC3#3 threads (91 and 60 mg/dl, respectively), as compared to animals that were injected with wild type BHK cells (42 and 23 mg/dl, respectively). The zins1N/PC3#3 threads-injected animals exhibited body weights and serum cholesterol levels comparable to those of the wild type BHK threads-injected animals, and did not appear or behave differently from the wild type BHK threads-injected animals.

In a third study, 8 month old db/db mice (very obese, severely diabetic) were injected with wild type BHK threads containing  $4 \times 10^7$  cells (n=7) or with zins1N/PC3#3 threads containing  $4 \times 10^7$  cells (n=6). Non-fasted animals were bled on days -4, 7, 13 and 17. At day 13, blood urea nitrogen levels (an indicator of kidney function) were lower in the animals that received zins1N/PC3#3 threads, as compared to the BHK threads control group.

## ii. Histology and Histomorphometry

The pancreas and spleen, a portion of the small intestine, omentum and any omental fat that might include pancreas were collected from 15 mice.

5           The tissues were fixed in 10% NBF (neutral buffered formalin; Surgipath, Richmond, IL) overnight. The pancreatic lobes were pressed together slightly to expose the largest pancreatic area to make every lobe of the pancreas flatten.

10           The tissue was dehydrated with a graded series of ethyl alcohols, cleared with xylene, and infiltrated with Paraplast X-tra (Fisher Scientific, Pittsburgh, PA) using a Tissue-Tek VIP2000 (Miles, Inc., Elkhart, IL).

15           The flattened pancreas was removed from the biopsy bag using forceps and embedded longitudinally with Paraplast X-tra. All pancreata were oriented the same way in the block, with the head of the pancreas placed in one corner of the embedding mold, the tail of the pancreas in the opposite corner, and the body in the middle of the  
20 mold.

Each section was trimmed with a Jung Biocut 2035 microtome (Bartels and Stout, Inc., Bellevue, WA) until the largest pancreatic profile area was exposed. Sections were cut at 3  $\mu$ m in thickness.

25           The sections were stained with Harris hematoxylin (Sigma, St. Louis, MO) and Eosin histology staining (Surgipath, Richmond, IL). The number and size of islets per longitudinal section of the pancreas were counted and measured by using a camara-lucida attached to  
30 a light microscope (10X objective, Olympus, BH-2), interfaced to a BioQuant System IV image analysis system (B&M Biometric, Inc., Nashville, TN). After calibration, the electronic pen of the digitizer was used to carefully trace the outline of each islet profile by screening the  
35 whole section of the pancreas. Simultaneously, the data was computed and stored. Data analyses were performed by

using ANOVA (GraphPad Software, San Diego, CA) followed by unpaired t test.

The results are shown in Figure 1 and Figure 2. Figure 1 illustrates a 50% increase in the number of islets present in samples taken from animals treated with BHK cells transfected with zins1 over animals treated with untransfected BHK cells. Figure 2 illustrates a trend toward increased size of islets seen in animals treated with BHK cells transfected with zins1 versus animals treated with untransfected BHK cells.

#### B. Administration of Zins1 Purified Protein

Purified zins1, that is produced by co-expressing the protein with PC3, is administered to normal mice to evaluate the effects on blood glucose and pancreatic islet histomorphometry. The duration of the study is 27 days with dosing for 20 days.

Female Balb/c mice, approximately nine weeks old are divided into the following treatment groups.

- Group 1: Vehicle (0.1% BSA/PBS), ip, n = 10
- Group 2: 1 µg zins1/PC3 per mouse (50 µg/kg), ip, n = 10
- Group 3: 5 µg zins1/PC3 per mouse (250 µg/kg), ip, n = 10
- Group 4: Untreated, n = 10

On day 0, mice are weighed, ear tagged and injected with 0.1 ml of the appropriate treatment solution. Animals are checked daily for behavioral and grooming changes, and body weights are determined weekly.

Labeling with BrdU (Zymed Laboratories, South San Francisco, CA), according the manufacturer's specifications is done from days 8-11 and from days 17-19 to label islet cells that are dividing in response to zins1.



Animals are bled on day 8 (a non-fasting sample) under ether anesthesia for clinical chemistry.

Mice are weighed and bled for serum on day 28. At necropsy, on day 28, the pancreas and a piece of gut  
 5 for BrdU control are collected. The pancreas is processed for histomorphometric analysis of islet size and number as described in A.ii., above. In addition, total cells and islets are analyzed for BrdU incorporation as described in Ellwart et al., Cytometry 6:513-520, 1985.

10

### Example 3. Purification and Characterization of Zins1 Protein

15

#### A. Purification of Zins1 Protein

The construct encoding the 124 amino acid Zins1 NF+PC3 (Zins1poZ2/PC3; described in Ex. 1) expressed in BHK cells was purified by affinity chromatography on anti-flag Sepharose (Eastman Kodak, Rochester, NY), according  
 20 to the manufacturer's specifications. Antigen was eluted with flag peptide, and further purified by gel filtration chromatography on Sepharose G-50 (Eastman Kodak). A total of 4.5 mg of Zins1 NF+PC3 was purified.

Analysis of the purified material by nonreducing  
 25 SDS-PAGE, followed by staining with Coomassie Blue, revealed a mixture of at least four peptides of apparent molecular weights 14,000-25,000. By staining, each of the four peptides was present in approximately equimolar amounts and each of these bands appeared to cross react  
 30 with anti-Flag antibodies upon Western blotting. Under reducing conditions, the electrophoretic profile was altered with each of bands exhibiting somewhat greater electrophoretic mobility. In addition, the major Coomassie Blue-stained protein observed under these  
 35 conditions was a protein of ~4 kDa. This band did not cross react with anti-Flag antibodies on Western blots.

Purified Zins 1NF +PC3 was probed on Western blots with each of three anti-Zins 1 peptide antibodies and anti-Flag antibodies as a control. The peptides used for antibody production in rabbits were:

5           Zins1-DC-1, LSQLLRESLAELRG, residues 16 to 30 of SEQ ID NO: 2 (spanning the putative N-terminus/ "B" chain junction);

          Zins1 -DC-2, LLESGRPKEMVSTSNKND, residues 57 to 75 of SEQ ID NO: 2 (the amino terminus of the "B" chain/"C" chain junction as predicted by Chassin et al., 1995, *ibid.*);

          Zins1 -DC-3, LKKIILSRKKRSGRHR, residues 104 to 119 of SEQ ID NO: 2 (spanning the putative "C" chain/"A" chain junction)

15           The anti-Zins 1-DC-1 antibody did not react with any band on reducing or nonreducing SDS-PAGE gels. Since only the five C-terminal residues of this peptide (i.e., residues 26-30 of SEQ ID NO: 2) were contained within the sequence of Zins1pOZ2/PC3, this indicated that no antibodies to this sequence were present. The lack of immunoreactivity also suggested that Zins1pOZ2/PC3 is correctly flag -tagged, since no crossreactivity was observed to amino acids N-terminal to the "B" chain junction.

25           The anti-Zins1 DC-3 did not react with any peptides on the Western blots, as well. These antibodies were directed against a peptide that spans the putative "C" chain/"A" chain junction. These results suggested that this region was cleaved during processing of the Zins1, a finding consistent with the PVDF blotting/sequencing. Lack of immunoreactivity with larger or smaller bands (unprocessed "B/C+A" or processed "B/C" and "A" chain) suggested that the epitope was at the "C" chain/"A" chain junction.

35           Results obtained with the anti-Zins1 -DC-2, antibodies directed against a peptide from the putative

"C"-peptide, were different. The reactivity looked identical to that observed with anti-Flag antibodies, namely reactivity was seen in several bands around ~20 kDa. These bands showed a small decrease in apparent size upon reduction.

#### B. Characterization of Zins1 Protein

The N-terminally tagged Zins1 protein purified above was characterized using N-terminal sequence analysis, glycosidase PAGE analysis, monosaccharide composition analysis and mass spectral analysis,.

N-terminal sequence analysis was done as follows:

A sample of Zins1, purified as described above, was run on a Novex 18% Tris-Glycine gel (Novex, San Diego, CA) under reducing conditions (2-mercaptoethanol). An electroblot transfer to PVDF membrane was performed in 10mM CAPS buffer pH 11.0, 10% methanol at 200mA for 1 hour at 4°C. The PVDF blot was visualized with Coomassie blue staining. Stained protein bands were excised for Edman degradation N-terminal protein sequencing on an Applied Biosystems 476A Protein Sequencer (Foster City, CA) using standard protocols and FSTBLT cycles. The data was analyzed using Applied Biosystems Model 610A Data Analysis System, v.1.2.2).

Liquid Chromatography - Mass Spectrometry (LCMS) was performed as follows:

A Michrom BioResources Magic 2002 HPLC system (Michrom BioResources, Inc., Auburn, CA) equipped with a 1.0 x 150 mm Monitor C18 100Å 5m column (Michrom BioResources, Inc.) was used at a flowrate of 50 µl/min and a column temperature of 30°C. Typically, 5.0 µg of whole or digested protein was injected onto the column equilibrated in 5% B and a linear gradient from 5 to 85% B over 80 minutes was immediately initiated (A: 2% acetonitrile + 0.1% acetic acid + 0.020% TFA, B: 90%

acetonitrile + 0.1% acetic acid + 0.018% TFA). The outlet from the HPLC UV detector was plumbed directly into a Finnigan LCQ Ion Trap Mass Spectrometer (Thermoquest Corp., San Jose, CA) with no flow splitting, a heated  
 5 capillary temperature of 220°C, and a sheath gas flow of 75 (arbitrary units). The source voltage was 5.60 kV and the capillary voltage was 41.00 V. Mass spectra from 300-2000 m/z were recorded continuously during the gradient with 3 microscans per full scan. The most intense  
 10  $[M+2H]^{2+}$  ion in each spectrum was automatically selected by the LCQ for zoom scan and MSMS at 25% collision energy.

As described above, initial SDS-PAGE analysis of the non-reduced, affinity purified Zins1 NF revealed a series of bands between 15-20 kDa. Upon reduction of the  
 15 protein, this series of bands shifts to 12-18 kDa and a new band appears with an apparent molecular weight of 4 kDa. While the non-reduced 15-20 kDa and reduced 12-18 kDa bands bind anti-FLAG antibody in a Western blot, the reduced 4 kDa band does not. N-terminal sequence analysis  
 20 was carried out on bands excised from a PVDF blot of an 18% Tris-Glycine reducing SDS-PAGE gel, specifically, the bands at 4, 12, and 18 kDa. The two high molecular weight bands both gave single sequences beginning at the first residue of the FLAG sequence, Residue 1 (Asp; SEQ ID NO:  
 25 5), and both continued through the expected N-terminal sequence for Zins1 NF to residue 25 (Leu) of SEQ ID NO: 5. The 4 kDa band was >85% single sequence beginning at residue 100 (Ser) and continuing through the expected sequence to residue 122 (Leu) of SEQ ID NO: 5. The  
 30 sequencing data corroborates the observed pattern in the Western blot with the upper molecular weight bands containing the FLAG sequence and the 4 kDa band containing no FLAG sequence. In addition the sequencing data indicates that Zins1 NF has been processed by the co-  
 35 expressed PC3 at the expected C/A junction, cleaving the protein after the residues 96-99 (ArgLysLysArg) of SEQ ID

NO: 5, to yield an A chain beginning at residue 100 (Ser) of SEQ ID NO: 5. Since the heterogeneity observed in the purified Zins1 NF is not due to differential processing of the polypeptide chain at the N-terminus or the C/A  
5 junction, it may be due to differential processing at the B/C junction or glycosylation events.

In order to ascertain if glycosylation is a factor in the observed heterogeneity, Zins1 NF was digested with PNGaseF and sialidase. Glycosidase PAGE  
10 analysis was performed as follows:

25 µg of protein was subjected to PNGaseF (peptide-N-glycosidase F) digestion. The protein was digested at 0.5 mg/ml protein and 0.2 U/ml Oxford GlycoSystems (Rosedale, NY) recombinant *F. meningosepticum*  
15 PNGaseF in 20mM sodium phosphate + 50mM EDTA pH 7.5. The digest was incubated at 37°C for 24 hrs. 5 µg of the treated protein was then analyzed by SDS-PAGE.

25 µg of protein was subjected to sialidase digestion. The protein was digested at 0.5 mg/ml protein and 4.0 U/ml Oxford GlycoSystems recombinant *C. perfringens* sialidase in 50 mM sodium acetate pH 5.0. The digest was incubated at 37°C for 24 hrs. 5 µg of the treated protein was then analyzed by SDS-PAGE.  
20

5 µg each of untreated, PNGaseF-treated, and sialidase-treated Zins1 NF was diluted with an equal volume of Novex 2X Tris-Glycine SDS sample buffer (Novex, San Diego, CA), boiled for 3-5 minutes, and loaded onto a Novex 18% Tris-Glycine gel. In addition, 5 µg each of untreated, PNGaseF-treated, and sialidase-treated Zins1 NF  
25 was diluted with an equal volume of Novex 2X Tris-Glycine SDS sample buffer (Novex, San Diego, CA) containing 5% β-mercaptoethanol, boiled for 3-5 minutes, and loaded onto a Novex 18% Tris-Glycine gel. Both the non-reduced and reduced gels were run at a constant voltage of 125V and  
30 visualized with Coomassie Blue staining. Novex Mark 12  
35

Wide Range Protein Standards were used to determine apparent molecular weights.

Non-reducing and reducing SDS-PAGE analysis of the PNGaseF-treated Zins1 NF revealed no differences relative to the untreated material. Treatment of Zins1 NF with sialidase resulted in a shift of the upper molecular weight bands to 14-18 kDa in the non-reducing gel and 12-16 kDa in the reducing gel, an average loss of ~1-2 kDa in apparent molecular weight. The band at 4 kDa in the reducing gel was unaffected. The results of the glycosidase treatment indicates that the single potential N-glycosylation site present in Zins1 NF, AsnLeuSer, residues 73-75 of SEQ ID NO: 5, is not glycosylated. However, the sialidase results suggest that Zins1 NF is O-glycosylated with sialylated O-glycans and that these O-glycans are not located on the A chain.

Confirmation of the putative O-glycosylation was obtained via monosaccharide composition analysis. Monosaccharide composition for Zins1 was analyzed as follows: Monosaccharide composition was carried out on a Dionex system composed of a DX500 HPLC with an ED40 electrochemical detector, a GP40 pump, and a CarboPac-PA 10 column (Dionex, Sunnydale, CA). In both types of analyses, Dionex monosaccharide standards were used to calibrate the instrument. The glycoprotein fetuin was used as a positive control (Sigma, St. Louis, MO).

For sialic acid analysis, 2-8 µg of Zins1 NF was vacuum centrifuged to dryness without heat and reconstituted in 500 µl of 0.1 N TFA. After mixing the samples were incubated at 80°C for 60 min., vacuum centrifuged to dryness without heat and reconstituted in 100 µl of distilled H<sub>2</sub>O. 25 µl of hydrosylate was injected onto the Dionex system equilibrated in 50 mM sodium acetate/ 100 mM NaOH. A gradient to 180 mM sodium acetate/100 mM NaOH over 25 minutes was used. Triplicate analyses were averaged.

For neutral monosaccharide analysis, 2-8  $\mu\text{g}$  of NF-zins1 was vacuum centrifuged to dryness without heat and reconstituted in 500  $\mu\text{l}$  of 2.0 N TFA. After mixing the samples were incubated at 100°C for 4 hours, vacuum  
 5 centrifuged to dryness without heat and reconstituted in 100  $\mu\text{l}$  of distilled  $\text{H}_2\text{O}$ . 25  $\mu\text{l}$  of hydrosylate was injected onto the Dionex system equilibrated in 18 mM NaOH. An isocratic separation at 18 mM NaOH over 25 minutes was used. Triplicate analyses were averaged.

10 Sialic acid composition analysis showed that Zins1 NF has  $6.0 \pm 0.5$  moles of sialic acid per mole of protein and that these sialic acids are N-acetylneuraminic acid (NeuNAc) and not N-glycolylneuraminic acid (NeuNGc) residues. Neutral monosaccharide composition analysis  
 15 showed that NF-zins1 has  $3.7 \pm 1.0$  moles N-acetylgalactosamine (GalNAc) and  $1.3 \pm 0.4$  moles galactose (Gal) per mole of protein. These figures are consistent with an average of 2.7 disialylated mucin-type O-glycans (NeuNAc $\alpha$ 2-3Gal $\beta$ 1-3 (NeuNAc $\alpha$ 2-6)GalNAc-Ser/Thr) on each  
 20 molecule of NF-zins1. No N-acetylglucosamine (GlcNAc) or fucose (Fuc) was detected and only a small amount of mannose ( $0.4 \pm 0.2$  moles mannose per mole protein), consistent with a lack of N-glycans.

LCMS analysis of reduced Zins1 NF resulted in a  
 25 very broad peak eluting from ~27-34 minutes with a sharp peak superimposed at 30.7 minutes. The broadness of the peak and the dearth of ions generated from it is typical of heterogeneous glycosylated proteins. One mass was discernible at 33.5 minutes, 12831.7 Da, a mass consistent  
 30 with that expected for uncleaved B/C chain (Asp1-Arg99, residues 1 to 99 of SEQ ID NO: 5) with 2 disialylated mucin type O-glycans, 12834.2 Da. Presumably the material eluting before this mass is more heavily glycosylated (and thus more heterogeneous) B/C chain. The peptide eluting at  
 35 30.7 minutes ionized well and has a mass of 2789.5 Da, consistent with the expected molecular weight (2789.2 Da)

of the predicted A chain, Ser100-Thr 124 (residues 100 to 124 of SEQ ID NO: 5).

LCMS and concurrent MSMS analysis of trypsinized native Zins1 NF revealed tryptic peptides from 89% of the complete sequence of Zins1 NF from Asp1 to Thr124. The tryptic peptides from the "C peptide" were not any less abundant than those from the "B chain" or A chain, suggesting that there is no B/C junction processing in Zins1 NF. A mass of 4289.5 Da was observed eluting at 29.4 minutes; the mass expected for Gly15-Arg19 + His23-Lys33 + His103-Thr124 (residues of SEQ ID NO: 5) joined by three disulfide bonds is 4289.0 Da. This observed mass is consistent with, though not exclusively, the disulfide bonding pattern expected from homology to the insulin family, i.e. Cys16-Cys110, Cys28-Cys123, and Cys109-Cys114 as shown in SEQ ID NO: 5. Furthermore, masses were observed that are consistent with tryptic peptide Thr34-Lys50 (as shown in SEQ ID NO: 5) + 0-1 O-glycans (27.6 minutes), Glu51-Lys79 (as shown in SEQ ID NO: 5) + 2-3 O-glycans (29.5 minutes), and Asp60-Lys79 (as shown in SEQ ID NO: 5) + 0-1 O-glycans (30.2-31.1 minutes).

The observed pattern of tryptic O-glycopeptides reveals that there are 4 O-glycosylation sites in the "C peptide" region of Zins1 NF. One site is contained in O-glycopeptide Thr34-Lys50 (as shown in SEQ ID NO: 5) and the modified residue is Thr34, Thr36, Thr37, Thr38, or Ser46 (as shown in SEQ ID NO: 5). Two sites are contained in O-glycopeptide Glu51-Lys59 (as shown in SEQ ID NO: 5) and the modified residues are Ser54, Thr55, and/or Ser56 (as shown in SEQ ID NO: 5). Finally, one site is contained in O-glycopeptide Asp60-Lys79 (as shown in SEQ ID NO: 5) and the modified residue is Thr66, Thr67, Ser68, or Ser75 (as shown in SEQ ID NO: 5).



Example 4. In Vitro Testing of Zinsl Protein

A. Isolation of Positive Control for Islet Proliferation Assay

5 To establish an assay to measure proliferation in islets *in vitro*, a positive control was isolated and characterized as fetal antigen 1 (FA1) as follows:

10 Pancreata from four 8-11 week old, p53 <sup>-/-</sup> male mice (Taconic Farms, Germantown, NY) were excised. The dissected pancreata were placed in a sterile 30 mm petri dish containing 7 ml of HBSS (Table 5) + 5 mM CaCl<sub>2</sub>, and the tissue was minced for exactly 2 minutes. Using a 10 ml pipet, the tissue was transferred to a sterile 25 ml screw-capped, round-bottom centrifuge tube, and 20 ml HBSS  
15 + 5 mM CaCl<sub>2</sub> was added. After settling (about 2 minutes), the supernatant (containing fat and connective tissue) was removed. This procedure was repeated twice.

24 mg collagenase (Collagenase Type XI, Sigma Chemical Co., St. Louis, MO) was dissolved in 12 ml HBSS +  
20 5 mM CaCl<sub>2</sub> just prior to use, and was kept on ice. The collagenase solution (6 ml) was added to the minced tissue to a final concentration of 2 mg/ml. The cell mixture was placed on a shaker (300 rpm at 37°C) for 15 minutes, and then quickly centrifuged for ~2 minute at 800 rpm in a  
25 Beckman CS-6R centrifuge with a swinging bucket rotor (Beckman Instruments, Palo Alto, CA). The supernatant was discarded.

6 ml fresh collagenase solution and 800 µl DNase were added, and the cell mixture was returned to the shaker for  
30 up to 20 minutes. 50 µl of cell mixture sample was added to 150 µl DTZ (Table 6), and was examined using a dissecting microscope to ascertain when the islet cells were isolated, but not over-digested.

When the islet cells were isolated, the collagenase  
35 digestion was stopped by adding 15 ml HBSS + 10% FBS to the mixture, and the mixture was then centrifuged in a

Beckman CS-6R centrifuge with a swinging bucket rotor (Beckman Instruments, Palo Alto, CA) ~2 minutes at 800 rpm (the "wash step"). The supernatant was removed and discarded. The wash step was repeated two more times.

5 After washing, the cell pellet was resuspended in 2 ml HBSS, and the resuspended preparation was placed on two PERCOLL (Table 7) gradients (3 ml 40% PERCOLL and 3 ml 60% PERCOLL per 50 ml tube). One ml of this cell suspension was added to each tube. An additional 2 ml of HBSS was  
10 used to sequentially rinse the tubes from which the cell pellets were previously removed. This 2 ml of rinse suspension was added in 1 ml aliquots to each of the two gradients. Thus, each 50 ml tube had 2 ml of cell suspension on the top, then 3 ml of 40% PERCOLL, and  
15 finally 3 ml of 60% PERCOLL. The tubes were centrifuged in a Beckman CS-6R centrifuge with a swinging bucket rotor (Beckman Instruments) at 1850 rpm for 20 minutes, without the brake on.

After centrifugation, the top and bottom  
20 gradient interfaces were removed with a sterile transfer pipet, and each interface was transferred to a separate 50 ml tube. HBSS + 10% FBS was added to the interface and washed by centrifugation in a Beckman CS-6R centrifuge with a swinging bucket rotor (Beckman Instruments) for 10  
25 minutes at 925 rpm.

The top and bottom interfaces were filtered through a 70  $\mu$ m nylon cell strainer (Becton Dickinson & Co., San Jose, CA). The islet cells remained on the filter, and exocrine tissue passed through. The filter was flipped  
30 upside-down in a 60 mm petri dish, and the islet cells were washed into the dish. To ensure their isolation from other tissue, the islet cells were plucked into a clean 60 mm non-tissue culture-treated dish containing RPMI growth medium (Table 8) + 10% FBS. The islets were incubated at  
35 37°C, 5% CO<sub>2</sub> and the medium was changed at 24 and 48 hours.

Table 5HBSS

- 50 ml 10X HBSS  
 10 ml 1 M Hepes  
 5 2.4 ml 7.5% NaHCO<sub>3</sub>  
 5 ml PSN (100 X penicillin-streptomycin-neomycin)  
 Add sterile milli-Q water up to 500 ml and filter

Table 610 DTZ

- 10 mg DTZ (Sigma, St. Louis, MO)  
 1 ml DMSO, to dissolve DTZ  
 Make to 10 ml final volume with HBSS  
 Filter

15

Table 7PERCOLL

- 90% : 90 ml 100% PERCOLL + 10 ml 10X HBSS  
 60% : 30 ml 90% PERCOLL + 15 ml HBSS  
 20 40% : 20 ml 90% PERCOLL + 25 ml HBSS

Table 8RPMI

- 25 2.4 ml 7.5% NaHCO<sub>3</sub>  
 10 ml 1 M Hepes  
 5 ml 100 X PSN  
 5 ml 100 X Glutamine  
 RPMI-1640 (to a final volume of 450 ml)  
 30 50 ml fetal calf serum

Islets, obtained as described above, were placed in a 60 mm petri dish in RPMI + 10% FBS, and nine days later the whole islets were removed from the petri dish and replated in another 60 mm petri dish. Twenty one days later, the first dish was confluent, and the cells were removed with trypsin and passed into a T<sub>25</sub> flask.

Conditioned culture medium removed from these islet cells was added to cultures of normal BALB/c islets were isolated in Matrigel Basement Membrane Matrix (Collaborative Biomedical Products, Bedford, MA). The  
5 normal mouse islet phenotype changed, becoming huge with much branching and forming cyst-like structures. This conditioned medium was designated IDC53.1. Various other conditioned media obtained either from cultures of osteoclast, osteoblast or dendritic cells obtained from  
10 p53-/- knockout mice (see WO 9607733), or from cultures of normal C57/Black 6 islet cells, did not exhibit this activity. In addition, normal BALB/c islets placed in this conditioned medium developed "cobblestone" cells all around the islet. This effect was not seen when various  
15 other conditioned media were tested.

A BrdU incorporation study using BALB/c islets incubated with IDC53.1 conditioned medium (CM) was performed, to test whether there were cells within the islets that were proliferating. Briefly, one group of  
20 four T<sub>12.5</sub> flasks (Becton Dickinson) was inoculated with 100 islets each, and 5X IDC53.1 CM + 0.5% FBS was added to each flask. Another group of three T<sub>12.5</sub> flasks was inoculated with 100 islets each, and SFIF medium (serum free/insulin free medium; Becton Dickinson) + 0.5% FBS was  
25 added.

BrdU (Becton Dickinson) was added to the islet cell cultures daily, to a final concentration of 10  $\mu$ M. A flask from each group was harvested on days 4, 8 and 12. On day 8, two of the four flasks in the IDC53.1 CM test  
30 group were harvested. One of these flasks was used for an isotype control. The protocol and reagents for BrdU assay are available from Becton Dickinson Immunocytometry Systems, San Jose, CA, and were used according to the manufacturer's specifications.

35 For each harvested flask, the islets were harvested, washed twice in 1% BSA/PBS, and centrifuged at 800 rpm for

10 minutes. The pellet was resuspended in 200  $\mu$ l of 1X PBS on ice. Islets were slowly added to 2.5 ml cold 70% ethanol in a siliconized glass tube while maintaining a vortex. The islets were incubated on ice for 30 minutes, and the result was fixed islet cells. The fixed islets were centrifuged at 1000 rpm for 10 minutes at 10°C, and the ethanol was carefully removed.

One ml of 2 N HCl/Triton X-100 was slowly added to the cells, a few drops at a time, while maintaining a vortex. The mixture was incubated at room temperature for 30 minutes, to denature the DNA and produce single-stranded molecules. The preparation was centrifuged at 1000 rpm for 10 minutes, and then the supernatant was removed and the pellet resuspended in 1 ml of 0.1 M  $\text{Na}_2\text{B}_4\text{O}_7 \cdot 10 \text{ H}_2\text{O}$ , pH 8.5, to neutralize the acid. The resultant cells may be stored at this point by centrifuging, resuspending in cold 70% ethanol, and storing at -20°C.

The cells are then centrifuged at 1000 rpm for 10 minutes, washed with 1 ml of 0.5% TWEEN 20 in 1% BSA/PBS (TWEEN/BSA/PBS), and resuspended in 100  $\mu$ l TWEEN/BSA/PBS. To this resuspended preparation was added 20  $\mu$ l of FITC-labeled anti-BrdU antibody or isotype control. The mixture was incubated overnight on a shaker at 4°C for whole islets. Thereafter, the cells were washed 3 times using 1 ml TWEEN/BSA/PBS, where each wash was performed for at least 2 hours on the shaker. Preferable, the final wash is left overnight.

The islet preparation was then mounted on glass slides with depressions to prevent the islets from losing their shape. FluoroGuard Antifade Reagent (BioRad, Hercules, CA) was the mounting medium used. All positive BrdU cells per islet were counted for each of the three harvest days. On Day 4, there were 1.5 times more positive cells in the islets cultured in the 5X IDC53.1 CM than in the control. On Day 8, there were 2.9 times more

positive cells, and on Day 12 there were 3.5 times more positive cells, as compared to the control.

Islets were prepared as described above for a BrdU assay, but after incubation with the BrdU, the islets were  
 5 harvested, fixed, embedded, sliced and stained for anti-BrdU, anti-insulin, anti-glucagon and anti-somatostatin using standard immunohistochemistry techniques. The positive BrdU cells were also positive for insulin, and were negative for glucagon and somatostatin, strongly  
 10 suggesting that the cells are  $\beta$ -cells.

Using standard immunodepletion methods, it was demonstrated that FA1 was a factor in islet proliferation, and useful as a positive control for testing islet proliferation.

#### 15 B. Zins1 Testing in *In Vitro* Islet Assay

Normal BALB/c islets were isolated from 8.5 week old male mice. The islets were plated into a 96-well flat bottom plate, with approximately 15 islets/well in serum-free/insulin-free + 0.5% FCS medium, in duplicate. Zins1  
 20 diluted serum-free/insulin-free + 0.5% FCS medium was added at concentrations of 1-20 ng/ml, along with a negative control of serum-free/insulin-free + 0.5% FCS medium, and a positive control of conditioned medium as described in A.

25 At day 5, the wells to which positive control and all concentrations of Zins1 had been added, cells were proliferating, with optimal growth in the 1-10 ng/ml doses. At day 8, the 1-10 ng/ml dose range of Zins1 clearly contained adherent cells that appeared to be  
 30 growing from the islets. The cells which grew out of islets treated with Zins1 exhibited a spindle morphology in contrast to the FA-1 treated islets, which yielded cobblestone monolayers. Islets treated only with basal medium had no cell outgrowth and appeared senescent.

5

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

10

## CLAIMS

We claim:

1. A protein produced by a method comprising:  
culturing a host cell into which has been introduced a DNA expression vector comprising the following operably linked elements:  
a transcription promoter;  
a DNA segment comprising a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 76 to nucleotide 417;  
and  
a transcription terminator, wherein said host cell expresses the polypeptide encoded by said DNA segment; and  
recovering said protein.
2. The protein of claim 1, wherein the host cell is a mammalian cell.
3. The protein of claim 1, wherein the host cell has had a second DNA vector introduced into it, wherein said second expression vector comprises the following operably linked elements:  
a transcription promoter;  
a DNA segment encoding an endoprotease; and  
a transcription terminator, wherein said host cell expresses the polypeptide encoded by the DNA segment comprising a nucleotide sequence shown in SEQ ID NO: 1 from nucleotide 76 to nucleotide 417; and said DNA segment encoding said endoprotease.
4. An isolated and purified protein comprising:  
a first polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue 110 (Ser) or 114 (Arg); and  
a second polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 115 (Ser) to residue 139



(Thr), wherein said first polypeptide and said second polypeptide are capable of disulfide associating.

5. An isolated and purified protein comprising:

a first polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue selected from the group consisting of 48 (Lys), 49 (Thr) and 50 (Phe); and

a second polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 115 (Ser) to residue 139 (Thr), wherein said first polypeptide and said second polypeptide are capable of disulfide associating.

6. A method of stimulating proliferation of pancreatic islets comprising administering to a mammal in need thereof, an amount of an isolated and purified protein comprising:

a first polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue 110 (Ser) or 114 (Arg); and

a second polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 115 (Ser) to residue 139 (Thr), wherein said first polypeptide and said second polypeptide are capable of disulfide associating, sufficient to produce a clinically significant increase in insulin secretory capacity in said mammal.

7. The method of claim 6, wherein the clinically significant increase in insulin secretory capacity results in a decrease in fasting plasma glucose levels.

8. The method of claim 6, wherein the isolated and purified protein is administered in combination with an insulin sensitizer.

9. A method of stimulating proliferation of pancreatic islets comprising administering to a mammal in need thereof, an amount of an isolated and purified protein comprising:

a first polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue selected from the group consisting of 48 (Lys), 49 (Thr) and 50 (Phe); and

a second polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 115 (Ser) to residue 139 (Thr), wherein said first polypeptide and said second polypeptide are capable of disulfide associating, sufficient to produce a clinically significant increase in insulin secretory capacity in said mammal.

10. The method of claim 9, wherein the clinically significant in insulin secretory capacity results in a decrease in fasting plasma glucose levels.

11. The method of claim 9, wherein the isolated and purified protein is administered in combination with an insulin sensitizer.

12. A method for stimulating *in vitro* proliferation of pancreatic islet cells comprising culturing islets with an amount of an isolated and purified protein comprising:

a first polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue 110 (Ser) or 114 (Arg); and

a second polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 115 (Ser) to residue 139 (Thr), wherein said first polypeptide and said second polypeptide are capable of disulfide associating, sufficient to produce an increase in the number of islet cells as compared to islet cells cultured in the absence of said protein.

13. The method of claim 12, wherein said cells are cultured in 0.1 ng/ml to 100 ng/ml of said protein.

14. A method for stimulating *in vitro* proliferation of pancreatic islet cells comprising culturing pancreatic islets in an amount of an isolated and purified protein comprising:

a first polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 26 (Ala) to residue selected from the group consisting of 48 (Lys), 49 (Thr) and 50 (Phe); and

a second polypeptide comprising amino acid sequence as shown in SEQ ID NO: 2 from residue 115 (Ser) to residue 139 (Thr), wherein said first polypeptide and said second polypeptide are capable of disulfide associating, sufficient to produce an increase in the number of islet cells as compared to islet cells cultured in the absence of said protein.

15. The method of claim 14, wherein said cells are cultured in 0.1 ng/ml to 100 ng/ml of said protein.

Compositions and Methods for Stimulating Pancreatic Islet  
Cell Regeneration.

ABSTRACT OF THE DISCLOSURE

The present invention provides compositions for stimulating an increase in islet proliferation and  $\beta$ -cell mass using an insulin homolog polypeptide. The present invention also includes methods for treating diabetes by stimulating islet proliferation and  $\beta$ -cell mass increases and affecting insulin levels.

FIG.1





FIG. 2



**COMBINED DECLARATION FOR PATENT AND POWER OF ATTORNEY**  
(Includes Reference to PCT International Applications)

File No. 96-41

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**COMPOSITIONS AND METHODS FOR STIMULATING PANCREATIC ISLET CELL REGENERATION**

the specification of which (check only one item below):

☐ is attached hereto ☒ was filed as United States application Serial No. 08/991,890 on December 16, 1997

and was amended on \_\_\_\_\_

☐ was filed as PCT international application Number \_\_\_\_\_ on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate(s) or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate(s) or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:**

COUNTRY	APPLICATION NUMBER	DATE OF FILING	PRIORITY CLAIMED	
			<input type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO

I hereby claim the benefit under Title 35 United States Code 119(e) of any United States provisional application(s) listed below.

U.S. APPLICATION NUMBER	U.S. FILING DATE
60/033,003	December 16, 1996

I hereby claim the benefit under Title 35, United States Code 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, 1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT**

U.S. APPLICATIONS			STATUS (check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE		Patented	Pending	Abandoned
PCT APPLICATIONS DESIGNATING THE U.S.					
APPLICATION	FILING DATE	U.S. SERIAL NUMBERS ASSIGNED (if any)			

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Gary E. Parker	Deborah A. Sawislak	Debra K. Leith	Roberta A. Picard	Paul G. Lunn	Susan E. Lingenfelter
Reg. No. 31,648	Reg. No. 37,438	Reg. No. 32,619	Reg. No. 32,625	Reg. No. 32,743	Reg. No. 41,156

**Send Correspondence To:** Deborah A. Sawislak  
ZymoGenetics, Inc.  
1201 Eastlake Avenue East  
Seattle, WA 98102

**Direct Telephone Calls To:**  
Deborah A. Sawislak  
(206) 442-6672

1	Full Name	Family Name	First Given Name	Second Given Name
	Residence	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
2	Full Name	Family Name	First Given Name	Second Given Name
	Residence	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
3	Full Name	Family Name	First Given Name	Second Given Name
	Residence	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
4	Full Name	Family Name	First Given Name	Second Given Name
	Residence	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
5	Full Name	Family Name	First Given Name	Second Given Name
	Residence	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country
6	Full Name	Family Name	First Given Name	Second Given Name
	Residence	City	State or Foreign Country	Country of Citizenship
	Post Office Address	Post Office Address	City	State & Zip Code/Country

I hereby declare that all statement made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application any patent issuing thereon.

Signature of Inventor 1 <i>[Signature]</i>	Signature of Inventor 2	Signature of Inventor 3 <i>[Signature]</i>
Date Oct 13, 1999	Date	Date 10/13-99
Signature of Inventor 4 <i>[Signature]</i>	Signature of Inventor 5 <i>[Signature]</i>	Signature of Inventor 6 <i>[Signature]</i>
Date Oct 13, 1999	Date 10/13/99	Date 10/13/99



**COMBINED DECLARATION FOR PATENT AND POWER OF ATTORNEY**

(Includes Reference to PCT International Applications)

File No. 96-41

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOSITIONS AND METHODS FOR STIMULATING PANCREATIC ISLET CELL REGENERATION

the specification of which (check only one item below):

☐ is attached hereto ☒ was filed as United States application Serial No. 08/991,890 on December 16, 1996

and was amended on \_\_\_\_\_

☐ was filed as PCT international application Number \_\_\_\_\_ on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate(s) or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate(s) or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:**

COUNTRY	APPLICATION NUMBER	DATE OF FILING	PRIORITY CLAIMED	
			<input type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO
			<input type="checkbox"/> YES	<input type="checkbox"/> NO

I hereby claim the benefit under Title 35 United States Code 119(e) of any United States provisional application(s) listed below.

U.S. APPLICATION NUMBER	U.S. FILING DATE
60/033,003	December 16, 1996

I hereby claim the benefit under Title 35, United States Code 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, 1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT**

U.S. APPLICATIONS			STATUS (check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE		Patented	Pending	Abandoned
PCT APPLICATIONS DESIGNATING THE U.S.					
APPLICATION	FILING DATE	U.S. SERIAL NUMBERS ASSIGNED (if any)			

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Gary E. Parker	Deborah A. Sawislak	Debra K. Leith	Roberta A. Picard	Paul G. Lunn	Susan E. Lingenfelter
Reg. No. 31,648	Reg. No. 37,438	Reg. No. 32,619	Reg. No. 32,625	Reg. No. 32,743	Reg. No. 41,156

<b>Send Correspondence To:</b> Deborah A. Sawislak ZymoGenetics, Inc. 1201 Eastlake Avenue East Seattle, WA 98102	<b>Direct Telephone Calls To:</b> Deborah A. Sawislak (206) 442-6672
---	--

1	Full Name	Family Name Jaspers	First Given Name Stephen	Second Given Name R.
	Residence	City Edmonds	State or Foreign Country Washington	Country of Citizenship US
	Post Office Address	Post Office Address 5829 150th Place S.W.	City Edmonds	State & Zip Code/Country WA 98026/US
2	Full Name	Family Name Sprugel	First Given Name Katherine	Second Given Name H.
	Residence	City Seattle	State or Foreign Country Washington	Country of Citizenship United States
	Post Office Address	Post Office Address 10559 41st Place N.E.	City Seattle	State & Zip Code/Country Washington 98125/US
3	Full Name	Family Name Ren	First Given Name Hong	Second Given Name Ping
	Residence	City Kirkland	State or Foreign Country WA	Country of Citizenship CN
	Post Office Address	Post Office Address 104 10th Street South	City Kirkland	State & Zip Code/Country WA 98033/US
4	Full Name	Family Name Humes	First Given Name Jacqueline	Second Given Name M.
	Residence	City Seattle	State or Foreign Country Washington	Country of Citizenship US
	Post Office Address	Post Office Address 309 NE 52	City Seattle	State & Zip Code/Country WA 98105/US
5	Full Name	Family Name Hoffman	First Given Name Ross	Second Given Name C.
	Residence	City Seattle	State or Foreign Country WA	Country of Citizenship US
	Post Office Address	Post Office Address 503 13th Ave East #302	City Seattle	State & Zip Code/Country WA 98102/US
6	Full Name	Family Name Conklin	First Given Name Darrell	Second Given Name C.
	Residence	City Seattle	State or Foreign Country WA	Country of Citizenship CA
	Post Office Address	Post Office Address 2332 Minor Ave E Apt. 2	City Seattle	State & Zip Code/Country WA 98102/US

I hereby declare that all statement made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2 <i>Katherine H. Sprugel</i>	Signature of Inventor 3
Date	Date <i>10-17-99</i>	Date
Signature of Inventor 4	Signature of Inventor 5	Signature of Inventor 6
Date	Date	Date

## SEQUENCE LISTING

JC639 U.S. PTO  
09/518842  
03/03/00

## (1) GENERAL INFORMATION

- (i) APPLICANT: Jaspers, Stephen R.  
Sprugel, Katherine H.  
Ren, Hong Ping  
Humes, Jacqueline M.  
Hoffman, Ross C.  
Conklin, Darrell C.
- (ii) TITLE OF THE INVENTION: COMPOSITIONS AND METHODS FOR  
STIMULATING PANCREATIC ISLET CELL REGENERATION
- (iii) NUMBER OF SEQUENCES: 7
- (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: ZymoGenetics, Inc.  
(B) STREET: 1201 Eastlake Avenue East  
(C) CITY: Seattle  
(D) STATE: WA  
(E) COUNTRY: USA  
(F) ZIP: 98102
- (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Diskette  
(B) COMPUTER: IBM Compatible  
(C) OPERATING SYSTEM: DOS  
(D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:  
(A) APPLICATION NUMBER: 60/033,003  
(B) FILING DATE: December 16, 1996
- (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: Sawislak, Deborah A  
(B) REGISTRATION NUMBER: 37,438  
(C) REFERENCE/DOCKET NUMBER: 96-41

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 206-442-6672

(B) TELEFAX: 206-442-6678

(C) TELEX:

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 420 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION: 1...417

(D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG GCC AGC CTG TTC CGG TCC TAT CTG CCA GCA ATC TGG CTG CTG CTG	48
Met Ala Ser Leu Phe Arg Ser Tyr Leu Pro Ala Ile Trp Leu Leu Leu	
1 5 10 15	
AGC CAA CTC CTT AGA GAA AGC CTA GCA GCA GAG CTG AGG GGA TGT GGT	96
Ser Gln Leu Leu Arg Glu Ser Leu Ala Ala Glu Leu Arg Gly Cys Gly	
20 25 30	
CCC CGA TTT GGA AAA CAC TTG CTG TCA TAT TGC CCC ATG CCT GAG AAG	144
Pro Arg Phe Gly Lys His Leu Leu Ser Tyr Cys Pro Met Pro Glu Lys	
35 40 45	
ACA TTC ACC ACC ACC CCA GGA GGG TGG CTG CTG GAA TCT GGA CGT CCC	192
Thr Phe Thr Thr Thr Pro Gly Gly Trp Leu Leu Glu Ser Gly Arg Pro	
50 55 60	
AAA GAA ATG GTG TCA ACC TCC AAC AAC AAA GAT GGA CAA GCC TTA GGT	240
Lys Glu Met Val Ser Thr Ser Asn Asn Lys Asp Gly Gln Ala Leu Gly	
65 70 75 80	

ACG ACA TCA GAA TTC ATT CCT AAT TTG TCA CCA GAG CTG AAG AAA CCA	288
Thr Thr Ser Glu Phe Ile Pro Asn Leu Ser Pro Glu Leu Lys Lys Pro	
85 90 95	
CTG TCT GAA GGG CAG CCA TCA TTG AAG AAA ATA ATA CTT TCC CGC AAA	336
Leu Ser Glu Gly Gln Pro Ser Leu Lys Lys Ile Ile Leu Ser Arg Lys	
100 105 110	
AAG AGA AGT GGA CGT CAC AGA TTT GAT CCA TTC TGT TGT GAA GTA ATT	384
Lys Arg Ser Gly Arg His Arg Phe Asp Pro Phe Cys Cys Glu Val Ile	
115 120 125	
TGT GAC GAT GGA ACT TCA GTT AAA TTA TGT ACA TAG	420
Cys Asp Asp Gly Thr Ser Val Lys Leu Cys Thr	
130 135	

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 139 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Ala	Ser	Leu	Phe	Arg	Ser	Tyr	Leu	Pro	Ala	Ile	Trp	Leu	Leu	Leu
1				5				10					15		
Ser	Gln	Leu	Leu	Arg	Glu	Ser	Leu	Ala	Ala	Glu	Leu	Arg	Gly	Cys	Gly
		20						25					30		
Pro	Arg	Phe	Gly	Lys	His	Leu	Leu	Ser	Tyr	Cys	Pro	Met	Pro	Glu	Lys
		35						40					45		
Thr	Phe	Thr	Thr	Thr	Pro	Gly	Gly	Trp	Leu	Leu	Glu	Ser	Gly	Arg	Pro
		50				55					60				
Lys	Glu	Met	Val	Ser	Thr	Ser	Asn	Asn	Lys	Asp	Gly	Gln	Ala	Leu	Gly
65					70					75				80	
Thr	Thr	Ser	Glu	Phe	Ile	Pro	Asn	Leu	Ser	Pro	Glu	Leu	Lys	Lys	Pro
			85					90					95		
Leu	Ser	Glu	Gly	Gln	Pro	Ser	Leu	Lys	Lys	Ile	Ile	Leu	Ser	Arg	Lys
		100						105					110		

Lys Arg Ser Gly Arg His Arg Phe Asp Pro Phe Cys Cys Glu Val Ile  
115 120 125  
Cys Asp Asp Gly Thr Ser Val Lys Leu Cys Thr  
130 135

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 480 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence  
(B) LOCATION: 1...477  
(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG Met 1	GAT Asp	GCA Ala	ATG Met	AAG Lys 5	AGA Arg	GGG Gly	CTC Leu	TGC Cys 10	TGT Cys	GTG Val	CTG Leu	CTG Leu	CTG Leu	TGT Cys 15	GGC Gly	48
GCC Ala	GTC Val	TTC Phe	GTT Val 20	TCG Ser	CCC Pro	AGC Ser	CAG Gln 25	GAA Glu	ATC Ile	CAT His	GCC Ala	GAG Glu	TTC Phe 30	CAG Gln	AGA Arg	96
GGA Gly	CGC Arg 35	AGA Arg	CAT His	CAC His	CAT His	CAC His 40	CAT His	CAC His	GGT Gly	GGC Gly	TCC Ser 45	GGA Gly	GCA Ala	GAG Glu	CTG Leu	144
AGG Arg 50	GGA Gly	TGT Cys	GGT Gly	CCC Pro	CGA Arg 55	TTT Phe	GGA Gly	AAA Lys	CAC His	TTG Leu 60	CTG Leu	TCA Ser	TAT Tyr	TGC Cys	CCC Pro	192
ATG Met 65	CCT Pro	GAG Glu	AAG Lys	ACA Thr 70	TTC Phe	ACC Thr	ACC Thr	ACC Thr	CCA Pro 75	GGA Gly	GGG Gly	TGG Trp	CTG Leu	CTG Leu	GAA Glu 80	240
TCT Ser	GGA Gly	CGT Arg	CCC Pro	AAA Lys 85	GAA Glu	ATG Met	GTG Val	TCA Ser 90	ACC Thr	TCC Ser	AAC Asn	AAC Asn	AAA Lys	GAT Asp 95	GGA Gly	288

CAA GCC TTA GGT ACG ACA TCA GAA TTC ATT CCT AAT TTG TCA CCA GAG	336
Gln Ala Leu Gly Thr Thr Ser Glu Phe Ile Pro Asn Leu Ser Pro Glu	
100 105 110	
CTG AAG AAA CCA CTG TCT GAA GGG CAG CCA TCA TTG AAG AAA ATA ATA	384
Leu Lys Lys Pro Leu Ser Glu Gly Gln Pro Ser Leu Lys Lys Ile Ile	
115 120 125	
CTT TCC CGC AAA AAG AGA AGT GGA CGT CAC AGA TTT GAT CCA TTC TGT	432
Leu Ser Arg Lys Lys Arg Ser Gly Arg His Arg Phe Asp Pro Phe Cys	
130 135 140	
TGT GAA GTA ATT TGT GAC GAT GGA ACT TCA GTT AAA TTA TGT ACA TAG	480
Cys Glu Val Ile Cys Asp Asp Gly Thr Ser Val Lys Leu Cys Thr	
145 150 155	

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 159 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Asp	Ala	Met	Lys	Arg	Gly	Leu	Cys	Cys	Val	Leu	Leu	Leu	Cys	Gly
1				5				10						15	
Ala	Val	Phe	Val	Ser	Pro	Ser	Gln	Glu	Ile	His	Ala	Glu	Phe	Gln	Arg
			20				25						30		
Gly	Arg	Arg	His	His	His	His	His	Gly	Gly	Ser	Gly	Ala	Glu	Leu	
			35			40					45				
Arg	Gly	Cys	Gly	Pro	Arg	Phe	Gly	Lys	His	Leu	Leu	Ser	Tyr	Cys	Pro
		50			55		60								
Met	Pro	Glu	Lys	Thr	Phe	Thr	Thr	Thr	Pro	Gly	Gly	Trp	Leu	Leu	Glu
65				70			75						80		
Ser	Gly	Arg	Pro	Lys	Glu	Met	Val	Ser	Thr	Ser	Asn	Asn	Lys	Asp	Gly
			85				90						95		
Gln	Ala	Leu	Gly	Thr	Thr	Ser	Glu	Phe	Ile	Pro	Asn	Leu	Ser	Pro	Glu
			100				105						110		

Leu Lys Lys Pro Leu Ser Glu Gly Gln Pro Ser Leu Lys Lys Ile Ile  
           115                          120                          125  
 Leu Ser Arg Lys Lys Arg Ser Gly Arg His Arg Phe Asp Pro Phe Cys  
           130                          135                          140  
 Cys Glu Val Ile Cys Asp Asp Gly Thr Ser Val Lys Leu Cys Thr  
           145                          150                          155

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 124 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Asp Tyr Lys Asp Asp Asp Asp Lys Gly Ser Ala Glu Leu Arg Gly Cys  
   1                          5                          10                          15  
 Gly Pro Arg Phe Gly Lys His Leu Leu Ser Tyr Cys Pro Met Pro Glu  
           20                          25                          30  
 Lys Thr Phe Thr Thr Thr Pro Gly Gly Trp Leu Leu Glu Ser Gly Arg  
           35                          40                          45  
 Pro Lys Glu Met Val Ser Thr Ser Asn Asn Lys Asp Gly Gln Ala Leu  
           50                          55                          60  
 Gly Thr Thr Ser Glu Phe Ile Pro Asn Leu Ser Pro Glu Leu Lys Lys  
   65                          70                          75                          80  
 Pro Leu Ser Glu Gly Gln Pro Ser Leu Lys Lys Ile Ile Leu Ser Arg  
           85                          90                          95  
 Lys Lys Arg Ser Gly Arg His Arg Phe Asp Pro Phe Cys Cys Glu Val  
           100                          105                          110  
 Ile Cys Asp Asp Gly Thr Ser Val Lys Leu Cys Thr  
           115                          120

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

(2) INFORMATION FOR SEQ ID NO:7:

(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: Other  
(B) LOCATION: 7...14  
(D) OTHER INFORMATION: Xaa is any amino acid except Cys

Cys Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys  
1 5 10 15

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:                Stephen R. Jaspers, Katherine H. Sprugel, Hong  
   Ping Ren, Jacqueline M. Humes, Ross C. Hoffman,  
   Darrell C. Conklin

For:                                COMPOSITIONS AND METHODS FOR  
   STIMULATING PANCREATIC ISLET CELL REGENERATION

Filed:                              March 3, 2000

**LETTER**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

The computer readable form in this application is identical with that filed in Application Serial No. 08/991,890, filed December 16, 1997. In accordance with 37 CFR 1.821(e), please use the only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in the application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the specification of the instant application.

Respectfully submitted,



Deborah A. Sawislak  
Registration No. 37,438